Prisoners as Human Subjects: A Closer Look at the Institute of Medicine\u27s Recommendations to Loosen Current Restrictions on Using Prisoners in Scientific Research by Obasogie, Osagie K.
University of California, Hastings College of the Law
UC Hastings Scholarship Repository
Faculty Scholarship
2010
Prisoners as Human Subjects: A Closer Look at the
Institute of Medicine's Recommendations to
Loosen Current Restrictions on Using Prisoners in
Scientific Research
Osagie K. Obasogie
UC Hastings College of the Law, obasogieo@uchastings.edu
Follow this and additional works at: http://repository.uchastings.edu/faculty_scholarship
This Article is brought to you for free and open access by UC Hastings Scholarship Repository. It has been accepted for inclusion in Faculty Scholarship
by an authorized administrator of UC Hastings Scholarship Repository. For more information, please contact marcusc@uchastings.edu.
Recommended Citation
Osagie K. Obasogie, Prisoners as Human Subjects: A Closer Look at the Institute of Medicine's Recommendations to Loosen Current
Restrictions on Using Prisoners in Scientific Research, 6 Stan. J. C.R. & C.L. 41 (2010).
Available at: http://repository.uchastings.edu/faculty_scholarship/1359





PRISONERS AS HUMAN SUBJECTS: A 
CLOSER LOOK AT THE  INSTITUTE OF 
MEDICINE’S RECOMMENDATIONS TO 
LOOSEN CURRENT RESTRICTIONS ON 
USING PRISONERS IN SCIENTIFIC 
RESEARCH 
Osagie K. Obasogie† 
There have been notable discussions within scientific literature, bioethics 
scholarship, and the popular press regarding the Institute of Medicine’s (IOM) 
2006 recommendations to the Department of Health and Human Services to 
loosen federal restrictions on using prisoners in biomedical and behavioral 
research. Yet there has been little dialogue among legal scholars about the 
recommendations’ potential impact on administrative policy. Supporters point to 
the growing need for clinical trial participants, ethicists’ changing perspectives, 
and greater institutional protections, while opponents point to past abuses and 
their likelihood to reoccur. Although certainly at odds, a common underlying 
theme in this debate is a focus on the possible outcomes produced by these 
recommendations rather than examining the argument made by the IOM 
Committee in proposing changes to 45 C.F.R. § 46, Subpart C. While valuable, 
this focus on possible outcomes might obscure a critical question that has thus far 
remained relatively unexamined: did the IOM come to this recommendation for a 
substantial shift in regulatory policy in a rigorous manner? As part of a broader 
effort to think about ethics’ evolving relationship with administrative policy, this 
Article takes a closer look at the ethical framework used to justify these 
recommendations. Central to this inquiry is whether a proposed ethical 
framework that (a) is based upon a literature review of scholarship rather than 
an empirical examination of prison conditions, (b) treats prisoners’ vulnerability 
to abuse as solely a product of prison conditions without broader consideration 
of how profit motives within the research industry might exacerbate these 
concerns and (c) is isolated from other relevant normative commitments (such as 
human rights) can appropriately inform regulatory policy.  This Article argues 
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that it cannot. Before considering any changes to Subpart C, the Article argues 
that greater attention must be paid to how empirical methods can inform 
research ethics in prison, the different contexts that heighten prisoners’ 
vulnerability as human subjects, and the relevance of human rights to research 
ethics.   
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Rapid advances in biomedical research and changing perspectives in 
bioethics are leading to increased calls to reform many administrative policies 
related to health care, drug development, and clinical trials. One critical yet 
underexamined1 example of how evolving perspectives in research ethics are 
                                                
† Associate Professor of Law, University of California, Hastings; Associate Adjunct 
Professor, Department of Social and Behavioral Sciences, University of California, San 
Francisco; Senior Fellow, Center for Genetics and Society. B.A. Yale University, J.D. 
Columbia Law School, Ph.D. University of California, Berkeley. The author is grateful for 
comments on early drafts from Ashutosh Bhagwhat, Marcy Darnovsky, Lisa Ikemoto, Karen 
Maschke, Dorit Reiss, Keramet Reiter, Reuel Schiller, and David Winickoff. 
1. While the IOM’s recommendations have received notable discussion in medical and 
bioethics circles, a LexisNexis search shows that only a handful of law review articles 
reference or discuss the report. See, e.g., Andrea Lynn Osganian, Limitations on Biomedical 
and Behavioral Research Involving Prisoners: An Argument Supporting the Institute of 
Medicine’s Recommendations to Revise Regulations, 34 NEW ENG. J. ON CRIM. & CIV. 
CONFINEMENT 429 (2008); Gerald R. Prettyman, Jr., Ethical Reforms in Biotechnology 
Research Regulations, 15 VA. J. SOC. POL’Y & L. 51 (2007); Seema Shah, How Legal 
Injection Reform Constitutes Impermissible Research on Prisoners, 45 AM. CRIM. L. REV. 
1101 (2008); Keramet Reiter, Comment, Experimentation on Prisoners: Persistent 
Dilemmas in Rights and Regulations, 97 CAL. L. REV. 501 (2009); Rachel Wener, Comment, 
Not Situated to Exercise Free Power of Choice: Human Subject Research in Prison Settings, 
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calling for change in regulatory policy is the Institute of Medicine’s (IOM) 
recommendations to the Department of Health and Human Services to loosen 
federal restrictions (45 C.F.R. §§ 46.300 et seq.2) regarding the use of prisoners 
as human subjects in biomedical, epidemiological, and behavioral research.3 
Supporters point to the growing need for more clinical trial participants,4 
improved institutional oversight and greater penetration of ethical values into 
research norms and protocols since the current restrictions were implemented in 
the 1970s,5 and prisoners’ ostensible right to be included in biomedical and 
                                                                                                             
26 TEMP. J. SCI. TECH. & ENVTL. L. 365 (2007). In general, the non-legal scholarly 
conversation on the ethics of prison research has not been particularly robust in recent years. 
See, e.g., Kathleen Brewer-Smyth, Ethical, Regulatory, and Investigator Considerations in 
Prison Research, 31 ADVANCES IN NURSING SCI. 119 (2008); K.C. Kalmbach and Phillip M. 
Lyons Jr., Ethical and Legal Standards for Research in Prisons, 21 BEH. SCI. & L. 671 
(2003); Amy B. Smoyer et al., Compensation for Incarcerated Research Participants: 
Diverse State Policies Suggest A New Research Agenda, 99 AM. J. PUB. HEALTH 1746 
(2009); Sara Wakai et. al., Conducting Research in Corrections: Challenges and Solutions, 
27 BEH. SCI. & L. 743 (2009).  
2. Research Involving Prisoners, 45 C.F.R. §§ 46.301-.306 (2009). For a list of 
relevant Federal Regulations, see National Institutes of Health, Regulations and Ethical 
Guidelines, http://ohsr.od.nih.gov/guidelines/45cfr46.html (last visited Nov. 11, 2009). 
3. See generally COMM. ON ETHICAL CONSIDERATIONS FOR REVISIONS TO DHHS 
REGULATIONS FOR PROTECTION OF PRISONERS INVOLVED IN RESEARCH, INST. OF MED., 
ETHICAL CONSIDERATIONS FOR RESEARCH INVOLVING PRISONERS (Lawrence O. Gostin et al. 
eds., 2006) [hereinafter 2006 IOM REPORT]. While the IOM Committee’s intent is for its 
recommendations to apply to all types of research with human subjects (biomedical, 
social/behavioral, and epidemiological), this Article largely discusses the recommendations 
in the context of biomedical research since (1) this type of research has the most significant 
risks and, as result, is most fraught with ethical challenges and (2) most of the discussion 
concerning the IOM Committee’s recommendations has referenced this context. 
4. The FDA “is requiring more tests and longer tests of new drug candidates” and 
“[b]iotechnology companies, thanks in part to the decoding of the human genome and other 
advancements in drug-development technology, are generating a swelling pool of new drug 
candidates that need to be tested.” John George, Drug Trials Cause Tribulations: Finding 
Volunteers is Becoming Tougher Task, PHILA. BUS. J., Dec. 5, 2008, available at 
http://philadelphia.bizjournals.com/philadelphia/stories/2008/12/08/story1.html.  
Yet, 
 finding people . . . to test new drug products or medical devices is becoming more 
challenging than ever before” because “adverse events — ranging from a teenager dying in a 
University of Pennsylvania gene therapy study to Merck pulling its FDA-approved arthritis 
pain medicine Vioxx off the market because of safety concerns — have tempered people’s 
willingness to participate in clinical trials. Id. 
5. According to Barron Lerner, 
It is often said that those who ignore history are condemned to repeat it. But a decision to 
retain current restrictions because of past abuses would ignore several important 
developments. Since 1978, a network of institutional review boards has been established at 
the National Institutes of Health, other governmental agencies, and research universities 
throughout the country. With “informed consent” now common parlance, study subjects are 
more aware of their rights. And, largely owing to the work of AIDS activists and breast 
cancer activists, sick and at-risk persons, even those from potentially vulnerable populations, 
now actively pursue participation in research protocols. Even though not all of these are 
unambiguously positive, to ignore them and the opportunities they may afford prisoners 
would be to regress. As the IOM report said, “Respect for prisoners also requires recognition 
of their autonomy.”  
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behavioral research.6 Critics tend to highlight past abuses and their likelihood 
to repeat themselves.7  
While at odds, this conversation’s high stakes have led both sides to largely 
focus on the possible outcomes of this proposed shift rather than to look more 
carefully at how normative claims emanating from ethics discourses are being 
leveraged to recommend substantial changes to regulatory policy. While it 
would be an overstatement to say that the prison research debate has been 
wholly consequentialist in nature, the current framing nonetheless takes the 
recommendations largely at face value without examining how the Institute of 
Medicine reasoned to its recommendations after 265 pages of ethical 
deliberation. This raises a central question: What methods, approaches, and 
assumptions did the IOM rely upon in recommending that current restrictions 
should be loosened?8 Was the IOM’s approach to research ethics—in terms of 
the methods used, the social contexts it identified as relevant to the issue, and 
the normative paradigms chosen to inform its decision-making—robust enough 
to justify overturning thirty years of regulatory precedent?  
This Article argues that it was not. Biomedical and research ethics offer 
many contributions for thinking through the proper relationship between 
doctors and patients as well as governments’ role in protecting human subjects 
in scientific research.9 While ethics certainly has a place in policy discussions, 
                                                                                                             
Barron H. Lerner, Subjects or Objects? Prisoners and Human Experimentation, 356 NEW 
ENG. J. MED. 1806, 1807 (2007). 
6. The exclusion of seriously ill prisoners from clinical trials through which they may 
receive potentially life-saving treatment is constitutionally dubious and morally troubling. It 
is arguable that prisoners have a right to participation under the Eighth Amendment, the Due 
Process Clause, and the promise of Equal Protection. In addition, moral considerations impel 
the allowance of prisoner enrollment in therapeutic biomedical research. 
Sharona Hoffman, Beneficial and Unusual Punishment: An Argument in Support of Prisoner 
Participation in Clinical Trials, 33 IND. L. REV. 475, 515 (2000). See generally David L. 
Thomas, Prisoner Research: Looking Back or Looking Forward?, 24 BIOETHICS 23 (2010).  
7. The United States has a lengthy history of abusing prisoners in the name of medical 
research. It was this well-documented history that led to the near prohibition of federally 
funded prisoner medical experimentation by the 1970s. The Institute of Medicine’s proposal 
to loosen these recommendations is ill-advised and shows a poor understanding of the 
modern American prison system.  
Paul Wright, Op-Ed., Look Elsewhere For Subjects, USA TODAY, Aug. 22, 2006, at 10A. 
8. While the IOM characterizes its recommendation as strengthening oversight 
mechanisms for research with prisoners, I use the term “loosen” to specifically describe the 
IOM’s proposed shift from prisoners’ categorical restriction to a risk/benefit approach. 
Compared to current regulations, this shift would likely lead to a substantial increase in the 
number of prisoners participating in scientific research. See infra Part II.C. 
9. For example, Kuhse and Singer note that bioethics “is a more overtly critical and 
reflective enterprise” that is distinguished in three different ways:  
First, its goal is not the development of, or adherence to, a code or set of precepts, but a better 
understanding of the issues. Second, it is prepared to ask deep philosophical questions about the 
nature of ethics, the value of life, what it is to be a person, the significance of being human. Third, 
it embraces issues of public policy and the direction and control of science.  
Helga Kuhse & Peter Singer, What is Bioethics? A Historical Introduction, in A COMPANION 
TO BIOETHICS 4 (Helga Kuhse & Peter Singer eds., Blackwell 2001) (1998). 
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this Article argues that it is not in and of itself a sufficient basis from which to 
develop public policy. This is where the IOM Committee’s report misses the 
mark. The IOM Committee largely treats its report as a scholarly exercise in 
ethics that should be adopted as regulatory policy rather than embracing its role 
as an independent government advisor that can provide the necessary 
bridgework to bring ethical inquiries into public policymaking in a robust and 
credible manner. This shortcoming is evident in at least three ways. First, from 
a methodological standpoint, the IOM Committee forgoes taking a serious 
empirical assessment (i.e. collecting primary data) of modern prison conditions 
and instead bases its updated ethical framework on a literature review of 
scholarly papers. Second, in terms of having an appropriate context from which 
to understand the ethics of prison research, the IOM Committee only situates its 
ethical inquiries into prisoners’ vulnerability by looking at prisons’ shifting 
demographics (racial disparities, health inequalities, etc.) without examining 
how shifting market conditions may lead researchers to treat vulnerable human 
subjects in a less than virtuous manner. Lastly, the IOM Committee does not 
meaningfully acknowledge other substantive sources that inform normative 
commitments to human subject protection outside of research ethics or 
biomedical ethics—namely human rights. Taken together, these 
methodological, contextual, and substantive critiques suggest that the IOM’s 
recommendations leave too much to be desired before they can meaningfully 
inform regulatory policy.  
This Article’s critique is broken into three parts. Part I briefly describes the 
Institute of Medicine in terms of its history, organization, and modern influence 
on health policy. After outlining the history of prisoners’ participation in 
scientific research in the twentieth century and the regulations implemented in 
the 1970s to oversee this practice, Part II describes the recommendations put 
forth by the Institute of Medicine as well as the updated ethical framework used 
to reach this conclusion. Part III then provides an extended discussion of the 
methodological, contextual, and substantive shortcomings of the Institute of 
Medicine’s ethical framework and recommendations. While these three 
critiques overlap at points, they nonetheless provide a useful analytic 
mechanism to think through the report’s limitations. This Article concludes by 
discussing how ethical inquiries can best serve future public policymaking 
endeavors.  
I. THE INSTITUTE OF MEDICINE: ORGANIZATION, STRUCTURE, AND INFLUENCE 
Positions taken by the Institute of Medicine carry significant weight as 
recommended public policy due to the IOM’s unique history and organizational 
structure. The IOM is one of four organizations that constitute the National 
Academies.10 The first of these organizations—the National Academy of 
                                                
10. The other organizations are the National Academy of Sciences, the National 
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Sciences (NAS)—was established after the Civil War for the specific purpose 
of advising the nation on matters of science. President Lincoln signed the Act 
of Incorporation on March 3, 1863. Section 3 of the Act lays out the basic 
parameters of the NAS:  
The Academy shall, whenever called upon by any department of the 
Government, investigate, examine, experiment, and report upon any subject of 
science or art, the actual expense of such investigations, examinations, 
experiments, and reports to be paid from appropriations which may be made 
for the purpose, but the Academy shall receive no compensation whatever for 
any services to the Government of the United States.11 
The National Academy of Sciences broadened its scope throughout the 
twentieth century at the request of several presidents to provide additional 
scientific advice to government. Under the original charter, the National 
Research Council was created in 1916 to “improve government decision 
making and public policy, increase public education and understanding, and 
promote the acquisition and dissemination of knowledge in matters involving 
science, engineering, technology, and health.”12 Also under the same charter 
signed by Lincoln, the National Academy of Engineering was founded in 1964 
to “provide[] engineering leadership in service to the nation.”13 It is comprised 
of over 2000 peer-elected members who provide expert research and analysis to 
many levels of government. 
Membership in the Institute of Medicine, which was founded in 1970, is 
highly selective and quite prestigious. As both an honorific society and a non-
profit organization charged with providing guidance to government on 
biomedical science, health, and medicine, the IOM has a strong reputation as an 
independent consultant to government. Indeed, the Institute of Medicine’s 
stated mission is to “serve[] as adviser to the nation to improve health,” which 
it does by providing “unbiased and authoritative advice to decision makers and 
the public.”14  
 The Institute of Medicine is organized in a manner that emphasizes 
impartiality and objectivity in its recommendations. It is a private, non-
governmental organization that does not receive any direct federal money for 
its services. The majority of its studies are conducted at the request of 
government agencies who then fund the work out of the federal appropriations 
                                                                                                             
Academy of Engineering, and the National Research Council. See The National Academies, 
http://www.nationalacademies.org/about/ (last visited Jan. 25, 2010).  
11. See National Academies of Science, About the NAS: Incorporation, 
http://www.nasonline.org/site/PageServer?pagename=ABOUT_incorporation (last visited 
Jan. 25, 2010).  
12. National Research Council, http://sites.nationalacademies.org/NRC/ (last visited 
Nov. 20, 2009). 
13. National Academy of Engineering, About the NAE, http://www.nae.edu/About. 
aspx (last visited Jan. 23, 2010).  
14. Institute of Medicine, About the IOM, http://www.iom.edu/About-IOM.aspx (last 
visited Jan. 24, 2010). 
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made available to them.15 State and local governments, foundations, and other 
independent organizations also suggest and provide support for studies.16 IOM 
members are elected by their peers based upon their scientific accomplishments 
and serve without compensation.17  
Much of the IOM’s influence and credibility comes from the rigorous 
study process behind each of its reports.18 This careful scholarly approach to its 
research along with its organizational structure allows the IOM’s reports and 
recommendations to have widespread influence among policymakers. Indeed, 
this influence is precisely why the federal government established the IOM and 
why their opinion is so highly sought: to affect policymaking.19  
Examples of this policy influence abound. The IOM’s Dietary Reference 
Intake20 provided “the scientific basis for the 2005 Dietary Guidelines for 
Americans—the government’s primary nutrition policy document . . . [and is] 
also credited with contributing to the removal of trans fats from foods.”21 
Saving Lives Buying Time,22 an IOM study on malaria drugs and their 
economics, is largely credited with “convinc[ing] a coalition of organizations, 
including the World Health Organization and the World Bank, to develop a 
worldwide subsidy program to make antimalarial drugs more affordable and 
available.”23 The Institute of Medicine engaged in a study on the quality of 
health care with its 2001 report entitled Crossing the Quality Chasm.24 Part of 
this series entailed a report on medical errors, which “inspired the creation of 
patient safety centers in several states to track and analyze data on hospital 
errors.”25 And an IOM Study entitled Injury in America26 “was a major 
                                                
15. See generally THE NATIONAL ACADEMIES, OUR STUDY PROCESS, available at 
http://www.nationalacademies.org/studycommitteprocess.pdf. 
16. See id. 
17. INST. OF MED., INFORMING THE FUTURE: CRITICAL ISSUES IN HEALTH 2 (5th Ed. 
2009), available at http://www.iom.edu/~/media/Files/Informing%20the%20Future%202009 
.ashx. 
18. See generally THE NATIONAL ACADEMIES, OUR STUDY PROCESS, supra note 15.  
19. The IOM’s work is organized into seventeen topic areas, including mental health, 
child health, public policy, public health and prevention, and minority health. See, e.g., 
National Information Center on Health Services and Health Care Technology, Introduction 
to Health Services Research: A Self-Study Course, available at http://www.nlm.nih.gov 
/nichsr/ihcm/03players/players16.html (last visited Jan. 25, 2010). 
20. PANEL ON DIETARY REFERENCE INTAKES FOR ELECTROLYTES AND WATER, 
INSTITUTE OF MEDICINE, DIETARY REFERENCE INTAKES FOR WATER, POTASSIUM, SODIUM, 
CHLORIDE, AND SULFATE (2004). 
21. INST. OF MED., ABOUT THE INSTITUTE OF MEDICINE: ADVISING THE NATION. 
IMPROVING HEALTH (on file with author) [hereinafter ADVISING THE NATION]. 
22. COMM. ON THE ECONOMICS OF ANTIMALARIAL DRUGS, INST. OF MED., SAVING 
LIVES, BUYING TIME: ECONOMICS OF MALARIA DRUGS IN AN AGE OF RESISTANCE (Kenneth J. 
Arrow, et al. eds., 2004).  
23. ADVISING THE NATION, supra note 21. 
24. COMM. ON QUALITY OF HEALTH CARE IN AM., INST. OF MED., CROSSING THE 
QUALITY CHASM: A NEW HEALTH SYSTEM FOR THE 21ST CENTURY (6th prtg. 2005).  
25. ADVISING THE NATION, supra note 21. 
41_82_OBASOGIE-PRINTER PROOF.DOC 11/9/10  4:30 PM 
48 STANFORD JOURNAL OF CIVIL RIGHTS & CIVIL LIBERTIES [VI:1 
contributor to the development of the injury control and prevention field.”27 To 
be sure,  
soon after Injury in America was released, Congress appropriated funds for a 
pilot program for injury control at CDC, and two years later, a new IOM-NRC 
[National Research Council] committee reviewed its progress. In Injury 
Control (NRC, 1988), the committee concluded that the program had been 
sufficiently successful to warrant permanent support. It commended the CDC 
program for establishing five interdisciplinary research centers; sponsoring a 
new program of extramural research; and building staff expertise for 
intramural research, database development, coordination, and technical 
assistance.28 
 While the Institute of Medicine’s effect on policymaking is not easily 
quantifiable, this anecdotal evidence along with its organizational mandate and 
structure suggests that it continues to have a significant influence on 
government decision-making. This also suggests that the Institute of 
Medicine’s recommendations concerning the loosening of restrictions on using 
prisoners in scientific research should be taken seriously; a long line of 
evidence implies that there is a strong likelihood that the federal government 
will give these recommendations careful consideration.29  
II. THE INSTITUTE OF MEDICINE AND ITS RECOMMENDATION TO LOOSEN 
CURRENT RESTRICTIONS ON PRISON RESEARCH 
In 2004, the Department of Health and Human Services’ (DHHS) Office 
for Human Research Protections commissioned the Institute of Medicine to 
“review the ethics regarding research involving prisoners.”30 In particular, the 
Institute of Medicine was charged with “examin[ing] whether the conclusions 
reached in 1976 by the National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research [1976 Commission] remain 
appropriate today.”31 The 1976 Commission was convened following the 
revelation of significant abuses in scientific research as a way to improve 
government oversight and human subject protection. To the extent that it is 
widely acknowledged that the 1976 Commission’s report “was the basis for 45 
                                                                                                             
26. COMM. ON TRAUMA RESEARCH, INST. OF MED., INJURY IN AMERICA: A CONTINUING 
PUBLIC HEALTH PROBLEM (1985).  
27. ADVISING THE NATION, supra note 21. 
28. COMM. ON INJURY PREVENTION AND CONTROL, INST. OF MED., REDUCING THE 
BURDEN OF INJURY: ADVANCING PREVENTION AND TREATMENT 20 (Richard J. Bonnie et al. 
eds., 1999). 
29. In a personal communication with Julia Gorey, Subpart C coordinator at the Office 
for Human Research Protections, she noted that no changes have been made to federal 
regulations based upon the IOM report but that changes to Subpart C are still under 
consideration. Communication with Julia Gorey, Office of Human Research Protections 
(Oct. 15, 2010) (on file with author). 
30. 2006 IOM REPORT, supra note 3, at ix. 
31. Id. at 22. 
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C.F.R. § 46”32—which provides federal regulations for human subjects 
research—and that the agency commissioning the report (DHHS) is the 
regulatory body that oversees and enforces these regulations,33 the IOM report 
has been largely seen as a serious attempt to rethink current restrictions on 
using prisoners in human subjects research.34 
The IOM report is the most recent chapter in a much longer conversation 
on using prisoners as human subjects. Before engaging in a detailed critique of 
the report, it is first necessary to (1) have a brief yet careful understanding of 
the history of conducting scientific research in American prisons and (2) 
engage in a close reading of the 1976 Commission’s report to appreciate the 
sensibilities leading to the current regulatory framework found at 45 C.F.R. § 
46, Subpart C. 
A. Background to the Current Regulatory Restrictions: Past Abuses wth Using 
Prisoners as Human Subjects 
Prisoners’ participation in biomedical and behavioral research was 
common in the United States throughout most of the twentieth century. Today, 
we largely associate unethical practices such as not obtaining subjects’ consent 
and coercion with Nazi medicine’s ghastly horrors.35 But these practices were 
                                                
32. Id. at 22-23. 
33. The Office for Human Research Protections (OHRP) provides leadership in the protection of 
the rights, welfare, and wellbeing of subjects involved in research conducted or supported by the 
U.S. Department of Health and Human Services (HHS). OHRP helps ensure this by providing 
clarification and guidance, developing educational programs and materials, maintaining regulatory 
oversight, and providing advice on ethical and regulatory issues in biomedical and behavioral 
research.  
U.S. DEP’T OF HEALTH AND HUMAN SERVICES, OFFICE FOR HUMAN RESEARCH 
PROTECTIONS FACT SHEET, available at http://www.hhs.gov/ohrp/about/ohrpfactsheet.htm 
(last visited May 2, 2010). 
34. The Institute of Medicine provides the following background to the commissioning 
of this report:  
 The OHRP’s responsibilities include implementation of the DHHS Regulations for the 
Protection of Human Subjects . . . and the provision of guidance on ethical issues in 
biomedical and behavioral research. OHRP has oversight and educational responsibilities 
wherever DHHS funds are used to conduct research involving human participants. The 
Secretary’s Advisory Committee for Human Research Protections (SACHRP), the advisory 
committee to OHRP, has asked OHRP to rewrite Subpart C, taking into consideration the 
current prison environment.  
 OHRP recommended that, before such an effort is undertaken, there should be a thorough 
review of the ethical considerations in research involving prisoners, which could serve as the 
basis for developing new regulations. Beyond its importance regarding revisions to Subpart 
C, such a review would be instructive for developing ethical bases for making future changes 
to the DHHS Regulations for the Protection of Human Subjects and the Common Rule.  
2006 IOM REPORT, supra note 3, at 24. 
35. See generally THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN 
HUMAN EXPERIMENTATION (George J. Annas & Michael A. Grodin eds., 1992) (discussing 
the implications of the Nuremberg trial and the subsequent impact of the Nuremberg Code 
on research ethics and international human rights). Annas and Grodin write,  
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far from unique to the Holocaust;36 ethical lapses led popular drugs such as 
Retin-A to be developed literally on prisoners’ backs before being 
mainstreamed into many Americans’ drug cabinets.37 To be sure, the 
questionable practices giving rise to the dramatic postwar increase in American 
prisoners’ human subject participation predated the Nuremberg trials by nearly 
half a century.  
As early as 1906, Dr. Richard P. Strong—director of the Biological 
Laboratory of the Philippine Bureau of Science who later became a professor of 
tropical medicine at Harvard—gave a cholera vaccine to twenty-four Filipino 
inmates without their consent in order to learn about the disease; thirteen died.38 
Though this provides an early modern example of using prisoners as human 
subjects, it certainly was not the last. Twelve inmates from Mississippi’s 
Rankin Farm prison became test subjects in 1915 to study pellagra—a 
disfiguring and deadly disease characterized by skin rashes and diarrhea. 
Though common wisdom at the time suggested that pellagra was a disease 
caused by germs, Dr. Joseph Goldberger—a physician in the federal 
government’s Hygienic Laboratory, predecessor to the National Institutes of 
Health—thought it was linked to malnutrition characteristic of Southern rural 
poverty. After Mississippi Governor Earl Brewer promised pardons to all 
participants—an inducement to participate in research that would be intolerable 
today—Goldberger tried to prove his theory that poor diet caused pellagra by 
subjecting inmates to what many called a “hellish experiment”: eating 
exclusively high-starch foods such as “corn bread, mush, collards, sweet 
                                                                                                             
[t]he most important historical forum for questioning the permissible limits of human 
experimentation was the trial of Nazi physicians in post-World War II Nuremberg, Germany. 
The trial provided the occasion for a substantive analysis of ethical standards. The physicians 
and professors prosecuted at Nuremberg represent a frightening example of medicine gone 
wrong. The extent of human experimentation, atrocities, and murders that were recorded 
during the trials is inescapable. 
 Id. at 3. 
36. [T]he Nazis were not the only ones to involve doctors in evil. One need only look at the role 
of Soviet psychiatrists in diagnosing dissenters as mentally ill and incarcerating them in mental 
hospitals; of doctors in Chile (as documented by Amnesty International) serving as torturers; of 
Japanese doctors performing medical experiments and vivisection on prisoners during the Second 
World War; of white South African doctors falsifying medical reports of blacks tortured or killed 
in prison; of American physicians and psychologists employed by the Central Intelligence Agency 
in the recent past for unethical medical and psychological experiments involving drugs and mind 
manipulation; and of the “idealistic” young physician-member of the People’s Temple cult in 
Guyana preparing the poison (a mixture of cyanide and Kool–Aid) for the combined murder-
suicide in 1978 of almost a thousand people. Doctors in general, it would seem, can all too readily 
take part in the efforts of fanatical, demagogic, or surreptitious groups to control matters of thought 
and feeling, and of living and dying.  
ROBERT JAY LIFTON, THE NAZI DOCTORS: MEDICAL KILLING AND THE PSYCHOLOGY OF 
GENOCIDE xii (1986). 
 37. See generally ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT 
HOLMESBURG PRISON 211-31 (1998). 
38. See generally Eli Chernin, Richard Pearson Strong and the Iatrogenic Plague 
Disaster in Bilibid Prison, Manila, 1906, 11 REV. INFECTIOUS DISEASES 996, 996 (1989). 
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potatoes, grits and rice” that caused considerable pain, lethargy, and dizziness.39 
Despite their pleadings to end the study, prisoners were not allowed to 
withdraw.40 And, in an early 1920s experiment that was as bizarre as it was 
gratuitous, 500 inmates at California’s San Quentin prison had testicular glands 
from rams, boars, and goats implanted into their scrotums to see if their lost 
sexual potency could be rejuvenated.41  
Though rare in the early twentieth century, these experiments highlight 
basic breaches in human subject protections that would be unconscionable 
under modern rules: the cholera test subjects had no idea what they were being 
infected with, the prisoners in the pellagra study were not allowed to stop their 
participation despite enduring substantial pain, and the San Quentin study’s 
purpose and mechanism were questionable. In all, prisoners were used during 
the early 1900s as convenience populations that had little control over their 
own health and welfare.  
World War II turned these small-scale endeavors into “considerably 
larger[,] broad-scale investigations that were adequately funded and well-
staffed.”42 The war played a central role in giving legitimacy to unbridled 
human experimentation in prisons.43 One infamous study was the Stateville 
Prison Experiments, where researchers deliberately infected over 400 state 
inmates with malaria in order to test treatments that were considered urgent for 
                                                
39. HORNBLUM, supra note 37, at 78. 
40. HORNBLUM, supra note 37, at 78-79. Hornblum writes, 
Goldberger would not allow [the prisoners to be returned to the general prison population]. 
They had volunteered; they would have to stay the course regardless of the physical 
consequences. [Soon] the first skin lesions began to appear and by the end of the month all of 
the men showed signs of a rash on their hands, faces, and scrotums, the typical markings of 
pellagra.  
Id., at 78.  
41. In 1918,  
Leo Stanley, resident physician of San Quentin prison in California . . . began transplanting 
testes removed from recently executed prisoners into older inmates, who in most cases 
testified to the recovery of sexual potency and the alleviation of many other illnesses. In 1920 
the “scarcity of human material” prompted him to substitute goat, deer and boar testes, which 
appeared to work equally well. 
E.J. Barten & D.W.W. Newling, Transplantation of the Testis; From the Past to the Present, 
19 INT’L J. OF ANDROLOGY 205, 206 (1996). 
42. HORNBLUM, supra note 37, at 80.  
43. Hornblum writes, 
The war years had become the transforming moment for human experimentation in America 
and particularly for penal institutions as a site of such scientific endeavors. What had once 
been a small, underfunded, unsophisticated cottage industry had blossomed into a well 
financed, broad clinical research programme investigating avant garde procedures, cures, and 
treatments. Human experimentation had been legitimised and prisoners had become the 
guinea pigs of choice for scores of inspired researchers. Public opposition to such medical 
initiatives was scant. The overriding goal was to win the war in Europe and Asia; everything 
else was secondary, including research ethics and the issue of consent. Millions of American 
fighters were risking life and limb daily; at the very least, lawbreakers could contribute to the 
war effort with similar commitment. And they did. 
Allen M. Hornblum, They Were Cheap and Available: Prisoners as Research Subjects in 
Twentieth Century America, 315 BRIT. MED. J. 1437, 1440 (1997). 
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aiding the war effort. The Stateville Experiments were troubling for many 
reasons. For example, investigators—led by the University of Chicago’s Dr. 
Alf S. Alving—used confusing consent forms to coax inmates into being 
injected with a life-threatening disease. Participation was also rewarded; 317 of 
the 432 inmates, including twenty-four murderers and one rapist, had their 
sentences commutated after participating.44  
Other wartime human subject research involving prisoners included efforts 
to find treatments for gonorrhea, gangrene, and influenza in addition to testing 
ultraviolet radiation’s effectiveness in killing airborne germs. The apparent 
patriotism and selflessness surrounding prisoners’ wartime volunteering not 
only led human experimentation to go unquestioned, but also led it to be seen 
as an affirmative good.45  
Prisoner experiments skyrocketed in the post-war era. Despite the horrific 
stories that came out of the Nuremberg trials and other narratives detailing Nazi 
research practices, medical researchers in the United States continued to go 
about their business without giving much thought to the Nuremberg Code or 
other emerging ethical principles.46 American exceptionalism and the 
increasing profit motive stemming from rapidly expanding research industries 
clouded opportunities for self-reflection, leading to inmates’ continued 
exposure to dangerous research.47 This included radioactive blood tests, live 
                                                
44. HORNBLUM, supra note 37, at 83.  
45. For example, 
[t]he U.S. Penitentiary at Atlanta, Georgia, played a critical role in the fight to conquer 
malaria and approached the challenge as if it were ‘a major military engagement.’ . . . 
.[Inmates were informed by government authorities] that malaria infection was taking a toll 
on American soldiers far in excess of Japanese soldiers. 
 Approximately 600 of Atlanta’s 2,000 inmates volunteered to become ‘human guinea 
pigs and undergo malarial infection and treatment with new drugs that were untried on the 
human system.’ 
 . . .  
 . . . Nearing the end of the experiment a reporter trumpeted the prison’s malaria project as 
‘another shining light in the galaxy of wartime achievements at Atlanta.’ 
Id. at 83-84. 
46. “The Nuremberg Code was widely regarded as ‘a good code for barbarians but an 
unnecessary code for ordinary physicians.’ . . . In general, there appeared to be a broad 
refusal among American medical scientists to draw lessons regarding their own actions from 
the Nuremberg medical trial.” Bruce Gordon & Ernest Prentice, Protection of Human 
Subjects in the United States, 6 J. PUB. HEALTH MGMT. 1, 3 (2000). 
47. Hornblum writes, 
  [O]nce the war was over, there was no decline of medical experimentation in prisons. 
Battlefield victories were replaced by medical triumphs as the focus of governmental 
concern, and prisoners were once again the subjects of choice for research. The eradication of 
disease had become the enemy, and postwar budgetary priorities supported this societal 
mission. For example, in the last year of the war, the National Institute of Health received 
about $700,000, which had climbed to $36 million by 1955, and over 10 times that just 10 
years later. In 1970, $1.5 billion was awarded to some 11,000 grant applicants, nearly a third 
of them performing experimentation. Called “the gilded age of research” by Professor David 
Rothman, this new era of laissez-faire attitudes in the laboratory ushered in a frenzy for 
research on prisoners that lasted for over a quarter century. Rothman argues that a “utilitarian 
ethic” was able to dominate the field of human experimentation because “the benefits seemed 
41_82_OBASOGIE-PRINTER PROOF.DOC 11/9/10  4:30 PM 
Apr. 2010] PRISONERS AS HUMAN SUBJECTS 53 
cancer cell injections, and even behavioral and mind control experiments. It 
was not uncommon for inmates to be either purposely given a disease or kept 
from safer alternatives in order to test experimental drugs or procedures. This 
quickly became standard fare: according to some reports, ninety percent of all 
new pharmaceuticals were tested on prisoners until the 1970s.48  
B. Mounting Concerns and Current Regulatory Framework 
Sensibilities began to shift in the 1970s with a number of revelations 
regarding the unethical treatment of vulnerable communities—both prisoners 
and non-prisoners. The growing criticism of human subjects research among 
the general population was ushered in by a number of events,49 but none so 
striking as the Tuskegee experiment where rural Black men with syphilis were 
deliberately left untreated so that researchers could study the course of the 
disease.50 However, public exposure of what was happening within prisons also 
played a key role. For example, it was during this period that the Holmesburg 
Prison experiments became public—where an array of human subjects studies 
coordinated in large part by the University of Pennsylvania used prisoners to 
explore everything from shampoo and deodorants to dioxin and chemical 
warfare materials. Major pharmaceutical companies were involved, such as 
Dow Chemical and RJ Reynolds, not to mention the United States Army.51  
With these revelations came the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research. This commission was 
created by the National Research Act, Pub. L. No. 93-348, 88 Stat. 342 (1974), 
                                                                                                             
so much greater than the costs” and because “there were no groups or individuals 
prominently opposing such an ethic.  
Hornblum, supra note 43, at 1439. 
48. Ian Urbina, Panel Suggests Using Inmates in Drug Trials, N.Y TIMES, Aug. 13, 
2006, § 1, at 1. 
49. By the early 1970s, social and political indifference to human experimentation had 
begun to shift. Events as disparate as drug scares (thalidomide), hospital embarrassments (the 
use of 22 senile patients for live cancer cell studies at the Jewish Chronic Disease Hospital in 
New York City), alarming articles in professional journals (Dr Henry Beecher’s analysis of 
unethical medical studies), and popular books (Jessica Mitford’s Kind and Usual 
Punishment) contributed to a growing repugnance towards scientific experiments on 
unwitting and institutionalized populations. 
Hornblum, supra note 43, 1440. 
50. Susan M. Reverby writes, 
 In the counties surrounding [Tuskegee, Alabama], the U.S. Public Health Service ran a 
forty-year study, from 1932 to 1972, of “untreated syphilis in the male Negro,” while telling 
the men in the study that they were being “treated” for their “bad blood.” The outcry over the 
study, which affected approximately 399 African-American men with the disease and 201 
controls, led to a lawsuit, Senate hearings, a federal investigation, and new rules about 
informed consent. It provided a powerful metaphor for racism, ethical mistakes, and the 
danger of state-run medical research. 
Susan M. Reverby, More Than Fact and Fiction: Cultural Memory and the Tuskegee 
Syphilis Study, 31 THE HASTINGS CTR. REP. 22 (2001).  
51. See generally HORNBLUM, supra note 37.  
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to “develop ethical guidelines for the conduct of research involving human 
subjects and to make recommendations for the application of such guidelines to 
research conducted or supported by [what is now called the Department of 
Health and Human Services.]”52 The Commission based its recommendations, 
published in 1976, on an examination of “the conditions under which such 
research is conducted, and the possible grounds for continuation, restriction or 
termination of such research.”53 To do this, “members and staff made site visits 
to four prisons and two research facilities outside prisons that use prisoners, in 
order to obtain first-hand information on the conduct of biomedical research 
and the operation of behavioral programs in these settings.”54 These visits 
included interviews with prisoners who had participated in research while 
incarcerated as well as with non-participants.55 
For the Commission, the task of developing ethical practices was as much 
of an empirical investigation56 as a principled one.57 These site visits provided a 
grounded assessment58 for what the Commission considered to be the key 
ethical consideration regarding prisoners’ human subject participation: “(1) 
whether prisoners bear a fair share of the burdens and receive a fair share of the 
benefits of research; and (2) whether prisoners are, in the words of the 
Nuremberg Code, ‘so situated as to be able to exercise free power of choice’— 
that is, whether prisoners can give truly voluntary consent to participate in 
                                                
52. NAT’L COMM’N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND 
BEHAVIORAL RESEARCH, REP. AND RECOMMENDATIONS: RESEARCH INVOLVING PRISONERS vii 
(1976) [hereinafter 1976 COMMISSION REPORT].  
53. Id. at viii. 
 54. Id. 
 55. Id. 
56. The Commission took pains to visit and survey different types of prisons across the 
country so that its recommendations would be informed by prisoners’ diverse experiences 
and institutional situations. They visited the State Prison of Southern Michigan at Jackson, 
which at the time was the largest prison in the United States with over 5000 inmates. To 
have a sense of behavioral programs operating in a prison setting, the Commission visited a 
unit of the Washington State Penitentiary at Walla Walla and the Michigan Intensive 
Program Center at Marquette. They also visited the California Medical Facility at Vacaville, 
which mostly held prisoners referred there for medical or psychiatric reasons. Id., at 33, 39. 
57. In their influential text on biomedical ethics, Tom Beauchamp and James Childress 
identify respect for autonomy, non-maleficence, beneficence, and justice as the four 
principles approach to biomedical ethics, which has become known as ‘principlism.’ They 
note that “the four principles derive from considered judgments in the common morality and 
medical traditions.” TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL 
ETHICS 23 (5th ed. 2001). 
58. In the 1976 Commission report, 
 [T]he Commission has noted and cannot ignore serious deficiencies in living conditions 
and health care that generally prevail in prisons. Nor can the Commission ignore the potential 
for arbitrary exercise of authority by prison officials and for unreasonable restriction of 
communication to and from prisoners. The Commission, although acknowledging that it has 
neither the expertise nor the mandate for prison reform, nevertheless urges that unjust and 
inhumane conditions be eliminated from all prisons, whether or not research activities are 
conducted or contemplated.  
1976 COMMISSION REPORT, supra note 52, at 5. 
41_82_OBASOGIE-PRINTER PROOF.DOC 11/9/10  4:30 PM 
Apr. 2010] PRISONERS AS HUMAN SUBJECTS 55 
research.”59 By explicitly referencing the Nuremburg Code, the Commission 
implied that the abuses conducted by American physicians and researchers 
raised concerns similar to those raised by scientists put on trial after World War 
II. To the extent that the American research industry did not see itself in this 
manner, drawing upon the Nuremburg Code to ground recommendations for 
American physicians’ behavior was a profound paradigm shift. To be sure, the 
Commission notes, “it is within the context of a concern to implement these 
principles that the Commission has deliberated the question of use of prisoners 
as research subjects.”60 
This sensibility led the Commission to take a protectionist approach in 
providing recommendations regarding prisoners’ participation in biomedical 
and behavioral research.61 In applying the basic ethical principles of justice 
(“that persons and groups be treated fairly”)62 and respect for persons (“that the 
autonomy of persons be promoted and protected”)63 the Commission forwent 
other interpretations and favored the protection of prisoners from abuse and 
exploitation:  
When persons seem regularly to engage in activities which, were they stronger 
or in better circumstances, they would avoid, respect dictates that they be 
protected against those forces that appear to compel their choices. It has 
become evident to the Commission that, although prisoners who participate in 
research affirm that they do so freely, the conditions of social and economic 
deprivation in which they live compromise their freedom. The Commission 
believes, therefore, that the appropriate expression of respect consists in 
protection from exploitation. Hence it calls for certain safeguards intended to 
reduce the elements of constraint under which prisoners give consent and 
suggests that certain kinds of research would not be permitted where such 
safeguards cannot be assured.  
 Further, a concern for justice raises the question whether social institutions 
are so arranged that particular persons or groups are burdened with marked 
disadvantages or deprived of certain benefits for reasons unrelated to their 
merit, contribution, deserts or need. . . . To the extent that participation in 
research may be a burden, the Commission is concerned to ensure that this 
burden not be unduly visited upon prisoners simply because of their captive 
status and administrative availability.64  
                                                
59. Id. 
60. Id. at 6. 
61. The Commission notes, 
[r]eflection upon [the principles of justice and respect for persons] and upon the actual 
conditions of imprisonment in our society has led the Commission to believe that prisoners 
are, as a consequence of being prisoners, more subject to coerced choice and more readily 
available for the imposition of burdens which others will not willingly bear. Thus, it has 
inclined toward protection as the most appropriate expression of respect for prisoners as 
persons and toward redistribution of those burdens of risk and inconvenience which are 
presently concentrated upon prisoners.  
Id. at 8. 
62. Id. at 5. 
63. Id. at 5-6. 
64. Id. at 6-7 (emphasis added). 
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While the Commission’s definitions of “justice” and “respect for persons” as 
motivating ethical principles may seem vague, they nonetheless gave substance 
to its protectionist approach that, in turn, led to five key recommendations.65 
 The Belmont Report66 informed new rules in the Code of Federal 
Regulations that strengthened all human subject protections.67 Additional 
subparts were added to provide specific protections for research involving 
vulnerable subjects—pregnant women, human fetuses, and neonates (Subpart 
B); prisoners (Subpart C); and children (Subpart D). Established in 1978, 
Subpart C reflects many of the recommendations put forth by the 1976 
Commission. It permits research with prisoners only when it falls within one of 
                                                
65. See generally id., ch. 2. The commission’s recommendations can be summarized as 
follows: (1) Studies of the possible causes, effects, and processes of incarceration and 
prisons as institutions may be conducted if they only present minimal risk or inconvenience 
to subjects. (2) Research on practices that are intended to improve prisoners’ health or well-
being are permitted. (3) Other studies that fall outside of the aforementioned parameters 
should not be permitted unless (a) they fulfill an important need and there are compelling 
reasons to use prisoners; (b) conditions of equity support the use of prisoners; and (c) there is 
a high degree of voluntariness among participants and openness by the institution. (4) The 
head of the responsible federal department should determine the investigators’ competency 
and the adequacy of the research facilities. Moreover, all research proposals involving 
prisoners should be approved by an Institutional Review Board (IRB). (5) Ongoing research 
projects that fall underneath the third recommendation shall continue until one year from the 
recommendations’ publication or their completion, whichever comes first. 
66. On July 12, 1974, the National Research Act (Pub. L. 93-348) was signed into law, 
there-by [sic] creating the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research. One of the charges to the Commission was to identify 
the basic ethical principles that should underlie the conduct of biomedical and behavioral 
research involving human subjects and to develop guidelines which should be followed to 
assure that such research is conducted in accordance with those principles. In carrying out the 
above, the Commission was directed to consider: (i) the boundaries between biomedical and 
behavioral research and the accepted and routine practice of medicine, (ii) the role of 
assessment of risk-benefit criteria in the determination of the appropriateness of research 
involving human subjects, (iii) appropriate guidelines for the selection of human subjects for 
participation in such research and (iv) the nature and definition of informed consent in 
various research settings.  
  The Belmont Report attempts to summarize the basic ethical principles identified by the 
Commission in the course of its deliberations. It is the outgrowth of an intensive four-day 
period of discussions that were held in February 1976 at the Smithsonian Institution’s 
Belmont Conference Center supplemented by the monthly deliberations of the Commission 
that were held over a period of nearly four years. It is a statement of basic ethical principles 
and guidelines that should assist in resolving the ethical problems that surround the conduct 
of research with human subjects. By publishing the Report in the Federal Register, and 
providing reprints upon request, the Secretary intends that it may be made readily available 
to scientists, members of Institutional Review Boards, and Federal employees. . . . 
  Unlike most other reports of the Commission, the Belmont Report does not make 
specific recommendations for administrative action by the Secretary of Health, Education, 
and Welfare. Rather, the Commission recommended that the Belmont Report be adopted in 
its entirety, as a statement of the Department’s policy.  
NAT’L COMM’N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL 
RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE 
PROTECTION OF HUMAN SUBJECTS (1979), available at http://ohsr.od.nih.gov/guidelines 
/belmont.html [hereinafter BELMONT REPORT]. 
67. 45 C.F.R § 46 (2009). 
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four categories:  
1. Studying the possible causes, effects, and processes of incarceration 
and/or criminal behavior, 
2. Studying prisons as institutional structures or prisoners as incarcerated 
persons  
3. Research on conditions that particularly affect prisoners as a class, and  
4. Research developed to improve subjects’ health and well-being. 
Minimal risk, or that the potential harm does not exceed what one might 
encounter in daily life or routine medical examination, is this subpart’s general 
standard. Under this framework (which only applies to research funded or 
conducted by the Department of Health and Human Services, Social Security 
Administration, CIA, or voluntarily compliant institutions68), “the default 
position is that no such research should occur, and the four or five categories of 
research allowed under the regulations are essentially exceptions to that general 
rule.”69  
C. The 2006 IOM Report and Its “Evolved” Ethical Framework for Evaluating 
Prison Research 
The Institute of Medicine’s 2006 report, Ethical Considerations for 
Research Involving Prisoners, was commissioned by the Department of Health 
and Human Services, whereby the charge of the Committee “was to explore 
whether the conclusions reached in 1976 . . . remain appropriate today.”70 
Weighing in at 265 pages, the report takes what appears to be an exhaustive 
look at all of the issues involved. Concluding that current restrictions should be 
loosened while boosting overall oversight, the IOM makes five major 
recommendations: 
1. Expand the definition of prisoner 
2. Ensure universal, consistent ethical protection  
3. Shift from a category-based to a risk benefit approach to research 
review 
4. Update the framework to include collaborative responsibility (e.g. 
developing research in collaboration with prisoners and prison staff) 
5. Enhancing oversight of research involving prisoners 
The first and last two recommendations are largely uncontroversial if not 
unequivocally beneficial in and of themselves. The first two, expanding 
oversight by including persons under any aspect of criminal justice supervision 
and ensuring universal ethical guidelines are surely an improvement over 
today’s patchwork of federal, state, and local rules. The last two, bringing 
                                                
68. Lawrence O. Gostin, Biomedical Research Involving Prisoners: Ethical Values and 
Legal Regulation, 297 JAMA 737 (2007). 
69. 2006 IOM REPORT, supra note 3, at 73. 
70. Id. at ix. 
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prisoners into the research process as collaborators and strengthening IRB 
oversight, will similarly find few opponents. The third recommendation—
shifting from prisoners’ almost categorical exclusion from research to a more 
permissive risk/benefit analysis—is where the ethical road meets the legal 
rubber. As such, this recommendation will be the focus of this Section.  
In describing how the 1976 Commission developed the current restrictions, 
the IOM report acknowledges the “commission’s emphasis on limiting research 
involving prisoners was guided by its choice of ethical framework.”71 Although 
the 2006 IOM Committee uses the term “ethical framework” throughout the 
report to both define core aspects of the 1976 Commission’s work and 
recommend substantial changes through an alternative approach, the IOM 
Committee does not define this concept precisely. A fair and plain reading of 
the IOM Committee’s usage of the term suggests that “ethical framework” is 
used to denote the ethical principles that guide each panels’ decision making 
with regards to the normative claims made about prisoner participation in 
scientific research.  
As discussed earlier, current regulations (informed by the 1976 
Commission’s ethical framework and findings) prioritize justice—defined here 
as whether prisoners are treated fairly and whether they bear a fair share of the 
research benefits and burdens—and respect for persons, which questions 
whether prisoners have enough personal autonomy to give voluntary consent. 
In short, the 1976 Commission felt that prison was no place to conduct 
widespread scientific research. The 2006 IOM Committee starts by creating “an 
updated ethical framework” based upon its conclusion that “ideas about justice 
and respect for persons have evolved over the past three decades.”72 Put 
differently, the 2006 Committee sidesteps the threshold issue concerning prison 
conditions presented by the 1976 Commission and instead asks whether ideas 
about ethical principles have changed. Its first evolutionary update is to 
“question[] the myopia caused by . . . a narrow focus”73 on informed consent. 
After reviewing a handful of articles, the Committee notes, “[m]ore attention 
needs to be paid to risks and risk-benefit analysis rather than the formalities of 
an informed consent document.”74 This shapes the major recommendation to 
stop thinking of prisoners as a category of individuals who, by default, should 
not be human subjects. Instead, the Committee recommends looking at each 
research proposal on a case-by-case basis to assess its potential risks and 
benefits.75 The Committee’s second evolutionary update is to expand justice 
                                                
71. Id. at 115. 
72. 2006 IOM REPORT, supra note 3, at 113, 116. 
73. Id. at 117. 
74. Id. at 118. While a risk/benefit approach is a new proposal in the context of prison 
research, such analyses are not uncommon in other aspects of human subjects research. See 
CARL H. COLEMAN ET AL., THE ETHICS OF REGULATION OF RESEARCH WITH HUMAN SUBJECTS 
ch. 6 (2005).  
75. The IOM Committee argues, “The risks and benefits of human subjects research 
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from its original meaning in 1976 to now include collaborative responsibility, 
or that prisoners be able to give input on research design. 
This shift from a substantive approach to justice and respect for persons 
(emphasizing protection, fairness, and burden-sharing) to a more procedural 
mechanism (emphasizing representation, along with the noncategorical 
risk/benefit analysis) constitutes the IOM Committee’s “evolved” or “updated” 
ethical framework. These changes represent the revised first principles from 
which the Committee recommends loosening current human subject restrictions 
for prisoners. The Committee believes that prisoners’ participation should no 
longer be highly restricted simply because they are prisoners, which runs 
directly against the 1976 Commission’s concern with prisoners as a category of 
human subjects to the extent “that the status of being a prisoner makes possible 
the perpetration of certain systemic injustices.”76 The 2006 IOM Committee 
suggests changing regulatory policies to cut in a different, more permissive 
direction: the benefits and risks of research should be weighed independently 
before a decision is made.  
 Before moving on to a critique of this shift away from prisoners’ 
categorical restrictions to a risk/benefit approach, it is important to note that the 
IOM Committee recognizes the concerns that may stem from its 
recommendations. Not only does it dedicate an entire chapter of the report to 
discussing oversight mechanisms and safeguards to accompany the 
recommendations, but it also provides specific guidance for conducting 
biomedical research with prisoners, which potentially carries the most risks.77 
Here, the IOM Committee recommends that in applying the risk/benefit 
framework in prison contexts, there should already be evidence of safety and 
efficacy (e.g., Phase III testing) and the ratio of prisoners to non-prisoners used 
in the study should not exceed fifty percent.78 (The Committee notes that these 
rules can be disregarded “in exceptional circumstances” and with additional 
safeguards.79) The IOM Committee emphasizes that biomedical research in 
prisons should only be done to benefit individual prisoners; inmates should not 
be used as a convenience population. While these additional protections are 
notable, this Article’s focus is on how the IOM Committee reasoned to the 
ethical propriety of its proposed risk/benefit approach to displace longstanding 
categorical restrictions, not the procedural mechanisms and limitations 
developed afterwards.   
                                                                                                             
are the ethically relevant issues, not the category of the research.” 2006 IOM REPORT, supra 
note 3, at 123. The Committee acknowledges that “weighing risks against benefits is 
inherently subjective,” but that such analysis should be based upon data to identify “the 
types of potential harms and benefits, their probability of occurrence, and their long term 
consequences.” Id. at 118. 
76. 1976 COMMISSION REPORT, supra note 52, at 7. 
77. See generally 2006 IOM REPORT, supra note 3, ch. 6. 
78. Id. at 126. 
79. Id. 
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III. BEYOND CONSEQUENCES: A CRITIQUE OF THE INSTITUTE OF MEDICINE’S 
RECOMMENDATIONS  
In an effort to assess the prevailing level of discourse and criticism, this 
Part begins by examining some of the commentaries published in scientific and 
public outlets in reaction to the Institute of Medicine’s recommendations. After 
highlighting the largely consequentialist nature of this commentary, this Part 
offers a critical assessment that draws attention to significant shortcomings in 
the IOM’s approach that have yet to be discussed.  
A. Existing Commentaries on the IOM Report 
The Institute of Medicine’s updated ethical framework and 
recommendations have not been discussed widely in legal literature, and the 
attention they have received in the scientific community,80 ethics scholarship,81 
and the popular press82 has been limited. While perspectives have been mixed, 
there has not been a robust scholarly critique of the reasoning and methodology 
behind the IOM’s proposed ethical stance on prisoners’ participation as human 
subjects. Georgetown Law Professor Lawrence Gostin, who chaired the 2006 
IOM Committee, wrote in the Journal of the American Medical Association 
(JAMA) that despite valid concerns, “[t]he opening of otherwise closed 
institutions to outside health professionals . . . could increase transparency and 
public accountability. Research can help society better understand how to 
improve prisoners’ chances to succeed.”83 Since the current regulations only 
apply to research supported or conducted by a handful or federal agencies and 
voluntary compliant organizations, the vast majority of prison-related research 
occurs with little oversight. Therefore, Gostin argues, the 2006 IOM 
Committee’s recommendations actually expand regulation by bringing all 
research involving incarcerated persons under the same framework. Barron H. 
Lerner agreed with the IOM Committee’s assessment in the New England 
Journal of Medicine, writing, “[t]he panel’s decision makes sense for several 
reasons.”84 Lerner notes that “despite the findings at Nuremberg and occasional 
other warnings, human experimentation was largely seen as a ‘good,’ 
                                                
80. See, e.g., Samuel Loewenberg, US Advisory Panel Revisits Prison Research Rules, 
368 THE LANCET 1143 (2006); Emily Waltz, US Ponders Unlocking the Gates to Prisoner 
Research, 12 NATURE MEDICINE 3 (2006).  
81. See, e.g., Eric Chwang, Against Risk-Benefit Review of Prisoner Research, 24 
BIOETHICS 14 (2010); Bernice S. Elger & Anne Spaulding, Research on Prisoners: A 
Comparison Between the IOM Committee Recommendations (2006) and European 
Regulations, 24 BIOETHICS 1 (2010); Thomas, supra note 6. 
82. See, e.g., Jeffrey Brainard, Report Calls for Easing Rules on Research Involving 
Prisoners, 52 CHRON. HIGHER EDUC., July 28, 2006, at A16; Urbina, supra note 48, at 1.  
83. Gostin, supra note 68, at 739.  
84. Barron H. Lerner, Subjects or Objects? Prisoners and Human Experimentation, 
356 NEW ENG. J. MED. 1806, 1807 (2007).  
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something that would advance science and benefit health.”85 To the extent that 
abuses took place during previous periods, Lerner argues that the advent of 
Institutional Review Boards in the late 1970s provides sufficient protection to 
prevent their reoccurrence. Moreover, Lerner argues that the idea that prisons 
are coercive environments that mitigate ideals such as informed consent “is a 
theory that can and should be investigated empirically,” and coercive elements 
are present in all research regardless of subjects’ imprisonment.86 Therefore, as 
another commentator notes, it is not uncommon within the research literature 
for people to conclude that the “type[s] of oversight described [by Lerner and 
Gostin], as well as in the Institute of Medicine Report, are likely to yield the 
benefits to incarcerated persons and minimize the risks of abuse.”87 
At first blush, it is striking that two prominent medical journals published 
articles strongly supporting a more permissive approach to using prisoners in 
scientific research. This type of support can also be seen in the bioethics 
literature. For example, David Thomas makes a familiar argument in the 
journal Bioethics that access to clinical trials give prisoners access to cutting 
edge therapies; denying this access simply because they are incarcerated may 
itself be unethical.88 Other commentators, however, have taken a more sober 
approach. Paul Wright, founder and editor of Prison Legal News, writes, “the 
key element to any ethical system of human subject testing is informed, 
voluntary consent. Prisons and jails fail on all counts. All 50 states and the 
federal government have banned sex among prisoners and staff because 
detention facilities are inherently coercive, and prisoners cannot give ‘consent’ 
in any meaningful sense of the word.”89 As the editor for a magazine that takes 
a human rights approach to incarceration, Wright is noticeably concerned that 
looser restrictions will result in abuses similar to those that occurred in the past. 
Investigative journalist Sonia Shah, an expert on the outsourcing of clinical 
trials to the developing world, argues that the Institute of Medicine’s 
recommendations have less to do with improving prisoners’ health or giving 
them access to cutting edge research and more to do with giving 
pharmaceutical companies access to human subjects when other volunteers are 
scarce. Moreover, Shah is not convinced that the IOM’s proposal for increased 
oversight for biomedical research in prison settings—such as limiting prisoner 
participation to Phase III trials and requiring that prisoners make up no more 
than half of all trial participants—are meaningful in light of broader 
                                                
85. Id. 
86. Id. 
87. Josiah D. Rich, Health Issues in Prisons and Jails, 84 J. URB. HEALTH 740, 741 
(2007). 
88. “[I]t is the feeling of many practitioners that the only way cutting edge therapy can 
be given to the incarcerated is through offering clinical trials in the prison setting. Likewise, 
denying them the advantages of cutting-edge treatments would be tantamount to abridging 
their rights only because of their incarcerated situation.” Thomas, supra note 6, at 25.  
89. Wright, supra note 7, at 10A. 
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dynamics.90 
B. Three Critiques of the IOM’s Updated Ethical Framework 
While the possible outcomes of the Institute of Medicine’s 
recommendations have received considerable attention, there has been little, if 
any, critique of the evolved or updated ethical framework developed by the 
Institute of Medicine to justify its more permissive approach. Put differently, 
how did the Committee come to its decision? What were the Committee’s 
reasons for supplanting the 1976 Commission’s ethical framework? How do 
they justify recommending a substantial departure from thirty years of 
regulatory policies regarding prisoners’ participation as human subjects? Are 
the reasons and ethical principles behind these justifications persuasive? Are 
there any limitations with the logic behind the IOM Committee’s new ethical 
framework? The Institute of Medicine report is certainly laudable in attempting 
to provide better oversight for prisoners’ participation as human subjects and 
reviewing whether the ethical commitments made three decades ago still serve 
prisoners’ best interest. Yet, there are at least three key critiques of the 
committee’s approach—spanning its methods, context, and substance—that 
raise serious questions about the Institute of Medicine’s more permissive 
ethical framework. 
1. Methodological Critique  
How we come to a particular decision is often as important as the decision 
itself. Thus, what is meant by critiquing the methods behind the Institute of 
Medicine’s report is to investigate the data, assumptions, conclusions, and 
arguments that inform the ethical choices that are made. What process did the 
                                                
90. For example, Shah discusses the difficulty of recruitment: 
  The bottleneck for drugmakers is in recruiting warm bodies for late-phase trials that 
establish a new product’s effectiveness with statistical certainty. These “Phase 3” trials can 
require tens of thousands of patients to complete, and most drug-saturated Americans are 
reluctant to take part. Eighty percent of trials fail to meet recruitment deadlines, bleeding 
drugmakers of $1 million a day while their blockbuster wannabes remain locked up in 
development.  
  To solve the dilemma, many drugmakers have rushed overseas, to places like India and 
Poland, where sick, desperate patients are abundant. Now, if the institute’s recommendations 
hold sway, they’ll be able to access the 7 million souls captive to the US correctional system 
as well. The institute’s proposed caveat that prisoner experiments include subjects from 
outside prison walls as well will make little practical difference in such trials. Few, if any, 
drugmakers would want to restrict these huge trials to prisoners anyway.  
Sonia Shah, Op-Ed., Testing Drugs on Prisoners: The Easy Out, BOSTON GLOBE, Aug. 17, 
2006, at A13. See also Leda M. Perez & Henrie M. Treadwell, Determining What We Stand 
For Will Guide What We Do: Community Priorities, Ethical Research Paradigms, and 
Research With Vulnerable Communities, 99 AM. J. PUB. HEALTH 201 (2009) (arguing that 
“until the question of adequate health care for prisoners is resolved, human experimentation 
should not be allowed.”).  
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Institute of Medicine Committee engage in to identify, collect, and analyze the 
data that informs its recommendations? And was this process robust enough to 
form the basis for a new ethical framework that suggests significant policy 
changes?  
The first methodological issue concerning the Institute of Medicine’s 
updated ethical framework stems from the fact that the Committee “visited one 
prison and one prison medical facility to discuss experimentation with current 
prisoners and peer educators.”91 This rather cursory first-hand look at the 
modern conditions of prison life is a stark contrast to the more in-depth 
examination made by the 1976 Commission, which based its recommendations 
on conditions observed during four site visits made to different types of prisons 
across the country. The 1976 Commission based its assessment on an empirical 
investigation into prisoners’ lived conditions and developed an ethical 
framework of protectionism that evolved out of its grounded assessment that 
basic ethical norms of justice and respect for persons would be difficult to 
achieve in a prison setting.92 Not only did the Institute of Medicine Committee 
not replicate the methodological rigor behind this approach, they also did not 
fully engage the conditional nature of the 1976 Commission’s sense of when 
these restrictions should be lifted: “should coercions be lessened and more 
equitable systems for the sharing of burdens and benefits be devised, respect 
for persons and concern for justice would suggest that prisoners not be deprived 
of the opportunity to participate in research.”93  
The 2006 IOM Commission’s lack of engagement with this conditional 
statement is notable. As a matter of precedent, that is where the 1976 
Committee left the conversation. Ethic’s engagement with precedent—not 
unlike precedent’s role in legal reasoning—can promote stability, consistency, 
and predictability that ultimately protect the most vulnerable parties involved. 
Many of the 2006 Committee’s recommendations can be read as providing a 
more equitable system of burdens and benefits sharing. But the issue of 
whether coercion has been lessened is an empirical question that is difficult to 
answer with one site visit. Moreover, it is also difficult to come to any policy 
recommendation—ethical in nature or otherwise—without committee members 
taking a more serious first-hand look at the conditions shaping modern prison 
life. This imperative is even more compelling if the committee’s leanings are to 
contravene three decades of ethical and administrative precedent to loosen 
restrictions initially developed to protect prisoners from exploitation. To the 
IOM Committee’s credit, it did collect information from six state corrections 
departments regarding their policies and practices pertaining to research with 
prisoners.94 But, there is a strong argument—particularly when judged by the 
                                                
91. 2006 IOM REPORT, supra note 3, at 122. 
92. See generally 1976 COMMISSION REPORT, supra note 52. 
93. Id. at 8. 
94. 2006 IOM REPORT, supra note 3, at 59. 
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standard set by the 1976 Commission—that this is insufficient for the 
Committee to gain an adequate appreciation for the unique challenges posed by 
conducting scientific research in a prison setting. This issue becomes even 
more relevant once one takes into consideration that all available evidence 
suggests that the conditions of prison life that might lead to coercion are 
unlikely to have improved and are most likely to have worsened since 1976.95  
This first critique concerning the Institute of Medicine’s cursory 
assessment of modern prison life is inextricably intertwined with a second 
methodological critique. Rather than engaging in an empirical understanding of 
prison conditions and how this may affect prisoners’ participation in scientific 
research, the Institute of Medicine relies heavily on shifting academic 
perspectives to form its ethical framework. What is remarkable, however, is 
that the Institute of Medicine Committee bases this new framework—which 
drives its policy recommendation to loosen restrictions—not on a substantial 
shift in the literature documenting prison experiences, but rather on what it 
calls an evolution in the ethics literature: 
Ideas about justice and respect for persons have evolved over the past three 
decades. To construct a comprehensive ethical framework for thinking about 
research in prisons, [we] explore[] recent research ethics scholarship. Changes 
in the way these principles have been conceptualized have influenced the 
shape of our recommendations.96  
Put another way, the committee bases its recommendations largely on a 
literature review. For example, the IOM Committee’s expanded view of respect 
for persons was informed by “recent scholarship [that] has questioned the 
myopia caused by such a narrow focus”97 on informed consent. They reference 
Kahn, Mastroianni, and Sugarman’s edited volume Beyond Consent: Seeking 
Justice in Research for the proposition that “[t]here seems to be agreement 
from a variety of perspectives that informed consent forms have consumed too 
much time and energy.”98 This leads the IOM Committee to question “whether 
too much weight has been placed on informed consent in the framework of 
research ethics and research regulation,”99 which ultimately leads them to state 
that “questions about an undue focus on informed consent influence [its] 
recommendations.”100 It is this literature review based critique of informed 
consent that shapes the Committee’s most significant recommendation to 
change current regulatory policy: the shift from treating prisoners as a 
                                                
95. For discussions of prison ethnographies that provide a close analytical look at the 
lived experiences of prisoners in today’s penal system, see, e.g., Jonathan Simon, The 
‘Society of Captive’s in the Era of Hyper-Incarceration, 4 THEORETICAL CRIMINOLOGY 285 
(2000); Loïc Wacquant, The Curious Eclipse of Prison Ethnography in the Age of Mass 
Incarceration, 3 ETHNOGRAPHY 371 (2002).  
96. 2006 IOM REPORT, supra note 3, at 116. 
97. Id. at 117. 
98. Id. 
99. Id. at 118. 
100. Id. 
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categorically excluded group (with few exceptions) to a more permissive 
risk/benefit assessment.101 Similarly, the IOM committee bases its 
recommendation to shift from a strong protectionist model (which was highly 
preferred by the 1976 Commission) to a moderate protectionist approach on the 
notion that “[a]dvances in ethical thinking about protectionism suggest a new 
regulatory model.”102 As a side note, it is interesting to point out that the IOM 
Committee provides additional justification for its more moderate approach to 
protectionism (and its ultimate recommendation to loosen restrictions) by 
pointing to empirical data gathered by the 1976 Commission in which several 
interviewed prisoners said that they appreciated the opportunity to participate in 
research103—a sentiment corroborated by other prisoners during the IOM 
Committee’s singular site visit. But what the IOM Committee fails to disclose 
is the extent to which the 1976 Committee found prisoners’ apparent 
willingness to participate irrelevant to the broader question of the ethics of 
using prisoners in research given their particular circumstances. The 1976 
Commission notes that it “did not find in prisons the conditions requisite for a 
sufficiently high degree of voluntariness and openness, notwithstanding that 
prisoners currently participating in research consider, in nearly all 
circumstances, that they do so voluntarily and want the research to continue.”104 
This methodological approach of using literature reviews as a basis for 
developing regulatory policy also informs the IOM Committee’s approach to its 
“evolved” understanding of justice. The first aspect of this evolution—
collaborative responsibility—stems from the Committee’s assessment that the 
“conceptualization of justice has expanded since the original [1976] 
commission’s work. They primarily thought of justice in terms of the 
distribution of risks and benefits.”105 The IOM Committee shifts this take on 
justice to include a concept of collaborative responsibility, which means that 
multiple stakeholders such as prisoners and representatives from outside 
community groups should participate in the conduct and design of research 
                                                
101. “More attention needs to be paid to risks and risk-benefit analysis rather than the 
formalities of an informed consent document.” Id. 
102. Id. at 121.  
103. The Institute of Medicine Committee notes that in 1975, commission members 
spoke,  
with a representative sample of research participants and nonparticipants selected by 
commission staff from a master list of all prisoners [in Jackson State Prison] and found that, 
overall, participants valued the opportunity to participate in research and felt they were 
sufficiently informed and free to enroll or withdraw at will, and nonparticipants did not 
object to this opportunity being available to others.  
Id. at 121-122.  
104. 1976 COMMISSION REPORT, supra note 52, at 12. With regards to the eagerness of 
the Michigan inmates to participate, the 1976 Commission placed this enthusiasm in a 
different context: “Participants gave many reasons for volunteering for research, including 
better living conditions, need for good medical evaluation, and desire to perform a 
worthwhile service to others, but it was clear that the overriding motivation was the money 
they received for participating.” Id. at 35 (emphasis added).  
105. 2006 IOM REPORT, supra note 3, at 127. 
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proposals that include prisoners.106 Working from Lisa Eckenwiler’s 2001 
article Moral Reasoning and the Review of Research Involving Human 
Subjects, the committee embraces this perspective to counterbalance its 
proposed risk/benefit shift away from prisoners’ categorical restrictions as 
human subjects.107 The IOM Committee also references scholarly work by Alex 
John London108 and Madison Powers109 to note that an evolved notion of justice 
“requires that [research with prisoners] must be done in a setting in which there 
is an adequate standard of health care in place.”110  
Although the ethical evolution involved in the IOM Committee’s new 
understanding of justice will find few objections, there are still significant 
methodological problems with basing policy recommendations on literature 
reviews, particularly with regards to the IOM Committee’s updated ethical 
framework on respect for persons. While there is certainly a place for assessing 
academic perspectives as part of the process of reviewing the adequacy of 
current regulations, prisons are profoundly unique environments whose every 
nuance and empirical reality must be brought into the policymaking process. 
There is a strong argument that the focus of the Committee’s ethical 
reasoning—that “[i]deas about justice and respect for persons have evolved 
over the past three decades”111—misses the point. The question is not simply 
whether academics, clinical practitioners, and other medical professionals have 
                                                
106. The IOM Committee notes this 
“involves acknowledging that groups are not monolithic and are themselves subject to a 
range of problems that should be addressed in the consultation process. This recommendation 
has two aspects: (1) including more lay people who match the local population and common 
subject groups in key respects; and (2) shaping IRBs so they are hospitable places for lay 
members.”  
Id. at 128. 
107. The IOM Committee writes, 
 [A] new risk-benefit approach needs to be accompanied by an emphasis on collaboration. 
The ethical problems associated with research involving prisoners will manifest themselves 
differently in each correctional setting. The one-size-fits-all approach characterized by a 
focus on informed consent cannot adequately address the unique concerns presented by each 
setting. Thus all relevant parties should be involved (prisoners, correctional officers, medical 
staff, administrators) when creating and implementing a research protocol. This effort, 
combined with a more specific focus on risks and benefits, can lead to research practices that 
better incorporate justice and respect for persons.  
Id. at 128-29. 
108. Alex John London, Justice and the Human Development Approach to 
International Research, 35 HASTINGS CTR. REP. 24 (2005). 
109. Madison Powers, Theories of Justice in the Context of Research, in BEYOND 
CONSENT: SEEKING JUSTICE IN RESEARCH 147-65 (Jeffrey P. Kahn et al. eds., 1998).  
110. 2006 IOM REPORT, supra note 3, at 132. The committee notes, 
that this expanded concept of justice is an important ethical development. Justice requires 
more than the protection of prisoners from harm caused by the research itself. Ethical 
research carries with it a responsibility to grapple with the fact that potential harm is 
ubiquitous in everyday prison life, creating an environment for research in which the choice 
to participate in a study can be inherently coercive and potentially dangerous. 
Id.  
111. Id. at 116. 
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changed their minds, but more importantly whether the conditions giving rise to 
the 1976 Commission’s ethical framework—such as coercion and lack of 
privacy—have been substantively addressed. The IOM Committee does not 
fully address this threshold question. 
To be clear, the IOM certainly identifies the ways prisons have changed 
since the 1976 Commission issued its report; an entire chapter in the IOM 
report examines today’s prisons in terms of shifting demographics, health 
issues, and the current environment.112 In addition to the prison and jail 
population’s astronomical growth since restrictions in prisoners’ human subject 
participation were implemented—from 454,444 inmates in 1978 to 2.1 million 
in 2004—the committee dutifully notes a number of challenges to conducting 
ethical human subjects research under these conditions. These include serious 
overcrowding, racial and ethnic disparities, disproportionately high rates of 
mental illness and chronic and infectious disease, poor health care, and high 
rates of violence, rape, and suicide. Nearly twenty-five percent of all inmates 
report being injured at least once since entering prison.113  
What is concerning, however, is that the IOM isolates these conditions in 
recommending greater oversight mechanisms—such as a public database for all 
research with prisoners—without discussing how these conditions bear on its 
chosen ethical framework, which drives its ultimate policy recommendation. 
Put differently, the realities of prison life are separated from the Committee’s 
investigations rather than integrated and grappled with as part of the 
fundamental ethical inquiry. As an example, for a prisoner who is routinely 
sexually assaulted by other prisoners—a situation not uncommon among 
today’s inmates114—what does privacy and informed consent mean and how 
would this shape said prisoner’s ability to freely participate in human subjects 
research that might adversely affect his health? By limiting concerns over 
prison conditions to questions of oversight rather than to the ethical propriety of 
using prisoners as human subjects, the report gives little guidance as to how to 
answer such questions.  
But the issue with the literature-review-as-public-policymaking approach is 
not simply that this method is problematic on its face, but also that the Institute 
of Medicine Committee uses this problematic method in a particularly 
problematic way. First and foremost, the literature review used to justify 
recommendations for substantial regulatory policy changes was not as robust as 
it could be. For example, to ground its claim that “[t]here seems to be 
agreement from a variety of perspectives that informed consent forms have 
consumed too much time and energy,”115 the IOM Committee points to one 
                                                
112. See generally id. 
113. See generally id. at 29-55. 
114. See generally HUMAN RIGHTS WATCH, NO ESCAPE: MALE RAPE IN U.S. PRISONS 
(2001).  
115. 2006 IOM REPORT, supra note 3, at 117. 
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edited volume.116 For such a broad statement about an entire scholarly field and 
its wide reaching implications—beyond the question of using prisoners as 
human subjects—it is reasonable to think that the IOM would engage in a more 
nuanced discussion of this issue before concluding “[t]hese questions about an 
undue focus on informed consent influence our recommendations.”117  
But in addition to the less than comprehensive nature of the Institute of 
Medicine’s literature review is the problem that very few of the key articles 
relied upon to give legitimacy to its updated or evolved ethical framework 
actually deal with the issue of conducting research in prisons.118 For example, 
Ezekiel Emmanuel et al.’s JAMA article What Makes Clinical Research 
Ethical? is heavily relied upon by the IOM Committee to justify its updated 
ethical framework. It substantially redefines informed consent and displaces 
categorical restrictions in favor of risk/benefit analyses. Yet, it does not discuss 
the unique ethical challenges posed by using prisoners as human subjects.119 
And, contrary to the Committee’s assertion that this article reflects the ethical 
evolution it proposes, the author states in the opening paragraph that traditional 
informed consent continues to “reflect[] the preponderance of existing guidance 
on the ethical conduct of research,”120 which belies the Committee’s argument 
that ethics as a field has evolved in a direction similar to its proposed 
framework. Similarly, albeit less problematically, the IOM Committee 
singularly cites Lisa Eckenwiler’s 2001 article as a basis for its evolved 
perspective on justice including collaborative responsibility when Eckenwiler’s 
discussion is not about the particular concerns raised by research in a prison 
context.  
These concerns point to substantial tensions within the IOM’s proposed 
ethical framework. In its attempt to discuss the ethics of doing research in a 
fraught and historically disfavored environment such as prisons, the IOM 
Committee reviews literature written outside of the prison context that does not 
address its particularities, abstracts the principles from this scholarship as 
universally applicable, and then reincorporates them as morally and 
                                                
116. See generally BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH (Jeffrey P. Kahn 
et al. eds., 1998). The IOM Committee cites to this one edited volume to ground its assertion 
that there is a consensus perspective among ethicists regarding informed consent. They cite 
to an article by Ezekiel Emanuel to discuss and ground an alternative risk/benefit approach, 
which they ultimately embrace.  
117. 2006 IOM REPORT, supra note 3, at 118. 
118. One exception is Jonathan Moreno’s “Convenient and Captive Populations,” 
which is part of the BEYOND CONSENT volume edited by Kahn et. al., which spends three and 
a half pages on conducting research in prisons. Jonathan D. Moreno, Convenient and Captive 
Populations, in BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH 113-16 (Jeffrey P. Kahn et 
al. eds., 1998). This article does not appear to have played a major role in the IOM’s 
decision-making, unlike other articles that were written against a distinctly non-prison 
backdrop. 
119. Ezekiel J. Emanuel et al., What Makes Clinical Research Ethical? 283 JAMA 
2701 (2000).  
120. Id.  
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situationally appropriate into an “updated” ethical framework that itself does 
not meaningfully engage with modern prison conditions. This is a strained 
methodology that privileges theory over lived conditions, which may very well 
be disastrous given prisoners’ vulnerable position.  
Nevertheless, the Institute of Medicine Committee may very well justify 
this method of inquiry by highlighting that the task charged to it by the 
Department of Health and Human Services was “to review the ethics regarding 
research involving prisoners.”121 By emphasizing that ethics is a humanistic 
field that has traditionally existed outside of empirical inquiries, the IOM might 
defend its methods by arguing that ethical inquiries typically entail 
philosophical investigation into the human condition that can be most clearly 
ascertained through the relevant scholarly literature. Moreover, it may 
reasonably defend its approach by saying that given the structure of its study 
process as well as other institutional imperatives, the Committee is neither 
equipped nor designed to engage the type of empirical scrutiny encouraged by 
this Article.122  
Yet, this explanation leaves much to be desired. While ethics is often 
identified as a philosophical endeavor anterior to empirical social science, a 
strong body of literature has developed over the past few decades that has led to 
a growing movement of “empirical ethics” or “evidence-based ethics” that 
entails “the application of research methods in the social sciences (such as 
anthropology, epidemiology, psychology, and sociology) to the direct 
examination of issues in bioethics.”123 Jacoby and Siminoff describe this shift 
through discussing the work of Renee Fox: 
[In 1989] Fox . . . produced an eloquent analysis of the relationship between 
bioethics and the social sciences characterizing it as “ . . . tentative, distant and 
susceptible to strain.” In her analysis, she described how each field contributed 
to the tension—bioethics largely due to its focus on individualism and 
equating the social sciences with a quantitative and non-humanistic 
perspective, and the social sciences due to their limited interest in studying 
values and beliefs and favoring structural and organizational variables which, 
she contended, reduced their understanding of the importance of ethical and 
moral values in society. Her conclusion was that the ethos of both fields, with 
resultant “blind spots,” constituted barriers to collaboration and synergy. 
 Since this bleak picture was articulated two decades ago, the relationship 
between the two fields has evolved to the point where bioethics is a 
multidisciplinary field of study (as opposed to a singular discipline), where 
moral philosophy, the medical sciences, the humanities, and the social 
sciences intersect.124 
                                                
121. 2006 IOM REPORT, supra note 3, at ix. 
122. See generally THE NATIONAL ACADEMIES, OUR STUDY PROCESS, supra note 17. 
123. Maya J. Goldenberg, Evidence Based Ethics? On Evidence-based Practice and 
the ‘Empirical Turn’ From Normative Bioethics, 6:11 BMC MED. ETHICS 1, 2 (2005), 
available at http://www.biomedcentral.com/1472-6939/6/11.  
124. LIVA JACOBY & LAURA A. SMINOFF, EMPIRICAL METHODS FOR BIOETHICS: A 
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Examples of the increasing incorporation of empirical methods into 
bioethics abound.125 At bioethics’ inception as a modern field of study in the 
mid 20th century, empirical methods were not widely used to explore issues 
such as human subject protections due to social scientists’ initial detachment 
from the field (which was then dominated by philosophers and theologians126), 
communication disjunctions across disciplinary boundaries, and meta-ethical 
distinctions between descriptive pursuits of “the is” and normative conclusions 
over “the ought.”127 Indeed, it was believed that empiricists and bioethicists 
operated in two distinct fields, where the former collected data and the latter 
assessed them.  But, the advantages of greater integration between the fields 
quickly became apparent in its ability to supplement abstract theory with 
practical accounts of reality.  That is, it has become increasingly acknowledged 
that credible accounts of what we ought to do should be grounded in an 
accurate assessment of lived conditions. This is precisely the contribution 
offered by empirical ethics. 
Hence, while the IOM Committee may have identified certain evolutionary 
trends in the field of ethics since the 1976 report, its failure to recognize this 
major trend towards grounding ethics in empirical assessments and its 
relevance to the Committee’s inquiry erects a substantial barrier to its 
recommendations. To not pursue a serious empirical investigation of how 
modern prison conditions shape the ethical question of research in this 
environment—let alone recognize the importance of such an investigation in its 
literature review—severely limits the report’s recommendations. Moreover, 
even if one concedes that a literature review is an appropriate basis for 
regulatory policymaking, then the review ought to be more substantive than 
citing one or two articles as a basis for recommending changes to over three 
decades of regulatory precedent. And if the study process for IOM Committees 
                                                                                                             
PRIMER 2 (Liva Jacoby and Laura A. Siminoff eds., 2008). 
125. For interesting overviews of the empirical turn in bioethics, see Richard E. 
Ashcroft, Constructing Empirical Bioethics: Foucauldian Reflections on the Empirical Turn 
in Bioethics Research, 11 HEALTH CARE ANALYSIS 3 (2003); Pacal Borry, Paul Schotsmans, 
and Kris Dierickx, The Birth of the Empirical Turn in Bioethics, 19 BIOETHICS 49 (2005).  
126. See generally ALBERT R. JONSEN, THE BIRTH OF BIOETHICS, chs. 2, 3 (1998).  
127. Descriptive ethics is the field in which empirical data about moral issues are gathered. 
It is the domain par excellence of sociology, anthropology, psychology, and epidemiology, 
and it aims at describing peoples’ temporal values, rules, preferences, norms, and actions. 
These disciplines describe how reality is constructed—they describe what ‘is.’ However, 
they can never tell how people ought to behave, or what kinds of decisions are morally 
acceptable. According to most authors, this fundamental distinction stems from a small 
paragraph of David Hume’s Treatise of Human Nature (1740), and is traditionally called the 
naturalistic fallacy. It is a logical mistake to infer a necessary conclusion from premises that 
are contingent in their modality, or to assign contingency to a conclusion that is inferred from 
premises that are necessary in their modality. The naturalistic fallacy consequently stresses 
that it is false reasoning to draw an ought-conclusion from premises that entirely consist of 
is-statements—one can never extrapolate an ‘ought’ from an ‘is.’ For this reason, ethicists 
became convinced that the results of social science research could never be useful for ethical 
reflection.  
Borry, et al., supra note 125, at 60. 
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cannot support empirical inquiries as basic as that which was pursued by the 
1976 Commission (e.g. multiple site visits across diverse penal institutions), 
then perhaps it is not the appropriate organization to weigh in on such issues.  
2. Contextual Critique  
The Institute of Medicine report uses past abuses with research in prisons 
as the main basis from which to situate its recommendations. This means that 
this history functions as the primary contextual backdrop informing how the 
IOM understands the situation, the risks and dangers involved, and the sensitive 
ethical terrain that needs to be navigated. This history provides a context that 
informs every aspect of the report, perhaps as a way to demonstrate a 
commitment to not allowing the past to become present. This is evident in 
different ways. The most explicit example is the report’s second chapter, where 
the Committee discusses current prison demographics, health issues, and 
research environment in relation to the past.128 This chapter provides a veritable 
laundry list of all the conditions that complicate the idea of conducting ethical 
research in prison environments—and how these conditions have worsened in 
just about every conceivable way. Health care is abysmal,129 the incarcerated 
population has exploded and prisons are overcrowded,130 racial minorities are 
disproportionately represented,131 the number of incarcerated women has 
                                                
128. The second chapter’s opening sentence reads, “The conditions of confinement in 
today’s prisons and jails have many of the same characteristics that were of concern to the 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research . . . some 30 years ago.” 2006 IOM REPORT, supra note 3, at 29. 
129. For example, the 2006 IOM report says, 
 Health care within some prison systems is less than satisfactory. . . . [A] federal district 
court judge placed California’s entire prison medical health-care system into federal 
receivership, taking it out of control of the state and placing it under the control of a trustee 
appointed by the court. In addition, the entire state prison mental health system is being 
monitored by another federal court after being found to be providing constitutionally 
inadequate mental health services to inmates with serious mental illnesses. . . . And New 
York regulators have faulted the private firm Prison Health Services in several deaths within 
the state’s prison system.  
Id. at 29-30. 
130. The IOM Committee notes “the correctional population has expanded more than 
4.5 fold between 1978 and 2004–from 1.5 million to almost 7 million. Prisons and jails 
house 2.1 million prisoners; an additional 4.9 million are on probation and parole.” Id. at 58. 
131. The report discusses racial disparities: 
 Blacks and Hispanics are disproportionately represented in prison and jail populations. At 
midyear 2004, an estimated 12.6 percent of all black males in their late 20s were in prisons or 
jails compared with 3.6 percent of Hispanic males and 1.7 percent of white males. Young 
Black men are particularly hit hard. One in eight black men in their late 20s is incarcerated 
on any given day. A report of the National Center on Institutions and Alternatives indicated 
that in the District of Columbia, 50 percent of young black men ages 18 to 35 were under 
criminal justice supervision (in prison, jail, probation, parole, out on bond, or being sought 
on a warrant).  
Id. at 38. 
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increased significantly,132 and prisoners are routinely exposed to violence.133  
But are changing prison demographics the only relevant context from 
which to think through the ethical challenges presented by using incarcerated 
people in scientific research? What is remarkable about how the IOM 
conceptualizes prisoners’ vulnerability is that it frames it largely as a function 
of “what happens in prisons” rather than the commercial forces that, in some 
instances, can lead researchers to seek prisoners in the first place. Put 
differently, the IOM Committee understands the potential for abuse stemming 
only from prison conditions, not the market conditions that can make prisons 
attractive places for research entities to find cheap and plentiful human subjects 
and perhaps not uphold the highest ethical standards. 
A bit of background may be helpful in understanding how the need for 
more human subjects intersects with research interests that may exacerbate 
prison research abuses. The same period that witnessed significant changes in 
prison demographics and conditions overlaps with a period of substantial 
changes in the pharmaceutical industry and clinical trial landscape. When Jonas 
Salk developed a polio vaccine in 1954, over 1.8 million people became “Polio 
Pioneers” by volunteering to test the experimental vaccination. People’s 
goodwill and trust were key to finding an effective treatment. Yet, these 
sentiments waned after the quickly approved vaccine was linked to accidentally 
infecting 220 children with polio. This, along with other human subject 
scandals such as Tuskegee, increased people’s skepticism and reluctance to 
volunteer.  
At the same time this human subject supply dwindled, genetic engineers 
began developing biotech techniques that sparked innovation and drug 
development. Sonia Shah notes, “[j]ust as the biotech revolution took off, the 
pipeline turning those new compounds into sellable products had started to 
clog.”134 There were “36,839 new clinical trials from 2001 to ‘04, six times 
                                                
132. “Between 1980 and 1998, the number of female inmates under the jurisdiction of 
federal and state correctional authorities increased more than 500 percent, from about 13,400 
in 1980 to roughly 84,000 at year end 1998, according to the U.S. General Accounting 
Office. In 2004, that number had risen to 104,848.” Id. at 35-36. 
133. The report acknowledges that,  
 [p]risoners face violence and injury within correctional settings. More than one-quarter of 
state and federal inmates reported being injured since admission to prison. The likelihood of 
injury increases with time served in prison, as does the likelihood of a medical problem.  
  In 2000, there were 34,355 assaults by state and federal prisoners against other inmates, 
and 51 prisoners died as a result of those violent actions. . . .  
  In 1999, nearly 22 percent of state inmates had a history of being injured while in 
prison. Overall, 7 percent of state inmates were injured in a fight while in prison.  
  According to the 2003 Prison Rape Elimination Act, more than 1 million people have 
been sexually assaulted in prisons over the past 20 years. The act also describes the 
devastating effects of sexual assault in this context: an increase in other types of violence, 
including murder, involving inmates and staff, and long-lasting trauma, which makes it even 
more difficult for people to succeed in the community after release.  
Id. at 47-48. 
134. SONIA SHAH, THE BODY HUNTERS: TESTING NEW DRUGS ON THE WORLD’S 
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more than in the period between 1981 to ‘85.”135  The rapid increase in drug 
development diametrically opposed the diminishing number of human subjects, 
creating considerable slowdowns in moving drugs from clinical trials to the 
market.  
This clog in the drug development pipeline has now turned into what many 
consider to be a full-blown crisis. Hundreds of new drugs that might save or 
improve lives are not reaching market as quickly as they might if human 
subject supply met demand. Drug development has largely outpaced human 
subject availability. But the crisis is not only humanitarian. It also affects the 
pharmaceutical industry’s bottom line. Central to a conversation that is 
ultimately about developing medicines to improve life is the reality that 
pharmaceuticals are big business. According to the Fortune 500 annual ranking 
of America’s largest corporations, pharmaceuticals had the third most 
profitable return on revenues of any industry in 2007.136 Like any other for-
profit endeavor, shareholders do not simply expect this performance to 
continue. They expect it to improve.  
Human subject shortages hamper drug companies’ humanitarian and 
shareholder interests; as much as $5 million is lost each day a new medication’s 
approval stalls, not to mention countless opportunities to improve patients’ 
lives.137 Eighty percent of all drugs tested on humans never receive FDA 
approval, partly as a result of this shortage.138 While the pharmaceutical 
industry did not play a formal role in the IOM’s recommendations, it would not 
be implausible to think that the inadequate supply of human subjects, their high 
demand, and the strong financial incentives to resolve this imbalance may have 
influenced the sensibility to relax current restrictions: 
Currently, there is a significant demand for pharmaceutical testing. From 1995 
to 2005, the contract research industry, grown out of the increasing need for 
subject recruitment for clinical trials, has grown from a 1 billion to a 7 billion 
dollar per year industry. Along with increasing testing needs has come high 
profile cases of drug toxicity, and these cases have created increased public 
awareness about the need for study and surveillance of drug toxicity. For 
example, it has been suggested that increased testing of Vioxx would have 
prevented the delay in discovering its cardiovascular toxicity.139  
Another financial pressure point exacerbating this human subject shortage 
is lost revenues associated with expiring patent exclusivity. For example, when 
                                                                                                             
POOREST PATIENTS 3 (2006). 
135. David Evans et al., Big Pharma’s Shameful Secret, BLOOMBERG MARKETS, Dec. 
2005, at 5.  
136. Fortune 500 Most Profitable Industries 2008, FORTUNE, May 5, 2008, available at 
http://money.cnn.com/magazines/fortune/fortune500/2008/performers/industries/profits/inde
x.html.  
137. Evans et al., supra note 135, at 6.  
138. Id. 
139. Timothy J. Wiegand, Captive Subjects: Pharmaceutical Testing and Prisoners, 3 
J. MED. TOXICOLOGY 37, 37 (2007).  
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Schering-Plough lost U.S. exclusivity on Claritin in December 2002, sales fell 
18% the following year; the company reported a net loss of $92 million 
compared to a $1.97 billion profit the previous year when their Claritin patent 
was secure.140 Market researchers estimate that drug companies making the 28 
top selling drugs will lose upwards of $50 billion in revenue as their patents 
expire between 2003-2008.141 The only way to stave off this tide is by 
developing new drugs, performing clinical trials to obtain FDA approval, and 
securing market exclusivity in new areas of pharmaceutical treatment. Human 
subjects are not only essential to the continuing health of an aging population, 
but also to these companies’ economic viability. Many pharmaceutical 
companies are already trying to fulfill this need by outsourcing clinical trials to 
developing countries.142 But more human subjects closer to home would surely 
be beneficial.  
It is surprising that the Institute of Medicine does not acknowledge how 
profit motives and market dynamics can play as significant of a role as prison 
conditions in giving rise to potentially abusive research environments. The 
search for new blockbuster drugs is a powerful motivator for corporations 
seeking to maintain their profitability. Sectors of the research industry 
immediately recognized how loosened regulations concerning prisoners’ 
participation in scientific research can dramatically improve their bottom lines, 
as noted in this pharmaceutical newsletter:  
The pharmaceutical industry, who said it was not involved in the panel’s 
decision, will be thrilled at the news, as it continues to struggle to recruit 
enough suitable patients for clinical trials. Patient recruitment is now 
consuming thirty per cent of clinical trial time—more time than any other 
clinical trial activity—and almost half of all trial delays result from patient 
recruitment problems. These delays are costing drug companies over half a 
million dollars for specialty products and more than $8m (€6.7m) for 
blockbuster brands in lost sales and are also causing the cost of running 
clinical trials to skyrocket. Meanwhile, the 2.3m-strong US prison population 
remains an untapped resource for patients who are perfect for clinical trials, 
including racial minorities, women, as well as people with mental illness and 
                                                
140. Evans et al., supra note 135, at 5. 
141. Evans et al., supra note 135, at 5. 
142. Shah writes, 
Just as automakers and apparel manufacturers had fled the stringent labor and environmental 
laws of the West to set up shop in the developing world, drug companies and [contract 
research organizations] streamed across the border. Although companies aren’t required to 
alert the FDA before testing their drugs on non-U.S. patients, nor does the FDA track 
research by location after approving new drugs, it is clear that the tectonic plates have 
shifted. Between 1990 and 1999 the number of foreign investigators seeking FDA approvals 
increased sixteenfold, the Department of Health and Human Services’ Office of the Inspector 
General found. By 2004, the FDA estimated, drug companies angling for FDA approval of 
their new products were launching over sixteen hundred new trials overseas every year. The 
most popular destinations are not Western Europe and Japan, but rather the broken, 
impoverished countries of Eastern Europe and Latin America. Russia, India, South Africa, 
and other Asian and African countries have proven equally fruitful. 
SHAH, supra note 134, at 7.  
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communicable diseases such as HIV/AIDS, hepatitis C, and tuberculosis.143 
The crucial role that human subjects play in the profitability of research efforts 
draws attention to the pressures that can lead to vulnerable populations’ 
questionable treatment by researchers.  
The Institute of Medicine Committee may respond to the critique that 
conditions beyond the immediate prison environment—such as the for profit 
drug development industry—might complicate these ethical questions by 
arguing that we should assume that researchers are virtuous in their endeavors. 
Indeed, this presumption that researchers can be trusted to protect human 
subjects drives the IOM Committee to move away from the strong protectionist 
approach favored by the 1976 Commission and towards a moderate approach: 
Advances in ethical thinking about protectionism suggest a new regulatory 
model. In particular, the committee rejects strong protectionism because it 
discounts the notion that researchers can be trusted to act virtuously in the 
protection of subjects. Researchers have responsibility for protecting subjects 
in their studies, especially those who are most vulnerable.144  
While the IOM Committee acknowledges that “given the troubling history 
of research abuse in prisons, weak protectionism is not an option,”145 the 
Committee’s blind normative assertion of the research industry’s categorical 
virtue may miss the point. Recommending that the protectionist sentiment 
embedded in current regulations should be revoked in favor of an approach that 
emphasizes placing the responsibility for human subject protection in the hands 
of the very industry that stands to profit from loosened regulations raises 
several questions concerning appropriate oversight.  
Regardless, there have been and continue to be numerous examples of the 
research industry’s failure to uphold basic research ethics regarding human 
subject protection, which belie the IOM Committee’s categorical confidence in 
preexisting institutional mechanisms. For example, an intriguing piece of 
investigative journalism from a 2005 Bloomberg Markets special report details 
how pharmaceutical companies engage private testing centers and private IRBs 
to coordinate their research efforts, including the recruitment of test subjects. 
The report notes: 
The FDA’s own enforcement records portray a system of regulation so porous 
that it has allowed rogue clinicians—some of whom have phony credentials—
to continue human drug tests for years, sometimes decades. The Fabre 
Research Clinic in Houston, for example, conducted experimental drug tests 
for two decades even as FDA inspectors documented the clinic had used 
licensed employees and endangered people repeatedly since 1980. In 2002, the 
FDA linked the clinic’s wrongdoing to the death of a test participant.  
                                                
143. Kirsty Barnes, Prisoners May Be Used to Fill Clinical Trial Patient Shortage, 
OUTSOURCING-PHARMA.COM, Aug. 17, 2006, http://www.outsourcing-pharma.com/Clinical-
Development/Prisoners-may-be-used-to-fill-clinical-trial-patient-shortage. 
144. 2006 IOM REPORT, supra note 3, at 121. 
145. Id. 
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 Review boards can have blatant conflicts of interest. The one policing the 
Fabre clinic was founded by Louis Fabre, the same doctor who ran the clinic. 
Miami-based Southern IRB has overseen testing at SFBC and is owned by 
Alison Shamblen, 48, wife of E. Cooper Shamblen, 67, SFBC’s vice president 
of clinical operations.146 
When such conditions and conflicts intersect with human subjects from 
vulnerable communities, there can be harmful effects for both the participants 
and research integrity. The Bloomberg Markets report details how 
undocumented persons evade basic research protocols and simultaneously 
participate in multiple clinical trials to get much needed cash.147 This puts their 
lives at risk in that unknown drug interactions can be deadly. Moreover, taking 
multiple drugs at once muddies the data the researchers analyze in order to 
determine safety and efficacy.148  
These are far from the only examples of questionable practices in the 
modern research industry. Pfizer has partially settled a lawsuit stemming from 
clinical trials of Trovan in Nigeria,149 where they allegedly tested a drug on sick 
children without written consent or legitimate ethics approval, leading to eleven 
deaths.150 A recent Congressional sting operation highlighted deficiencies in 
                                                
146. Evans et al., supra note 135, at 2.  
147. For example, 
Roberto Alvarez, 36, an Argentine in the U.S. on a visa; Efrain Sosa, 35, a Cuban native; and 
Marlon Matos, a 27 year old immigrant from Venezuela, say they’ve participated in more 
than one clinical trial in Miami at the same time or gone from one test to another, ignoring 
required waiting periods. They say they do it for the money, without telling the test centers, 
and that no one has ever caught them violating the rule.  
 “We maintain many safeguards to help ensure that the participants of our clinical trials 
are not participating simultaneously in multiple clinical trials,” SFBC’s Hantman says. SFBC 
fingerprints participants to keep track of their tests at the company, he says. “Unfortunately, 
there is no clearing house that we’re aware of that would allow us to find if they were 
participating in another trial at the same time.”  
 In April, Alvarez signed up for a 36-day clinical trial at Miami testing company Elite 
Research Institute for a new sustained-release form of donepezil, an Alzheimer’s drug that 
Tokyo-based Eisai Co. sells in the U.S. with New York-based Pfizer. At the time, Alvarez 
was in the middle of a 212-day test sponsored by Madison, New Jersey-based Wyeth at 
SFBC for an experimental muscular dystrophy drug, according to consent forms he signed. “I 
hop around to get around that,” says Alvarez, a part time construction worker. . . . “They ask, 
but I just don’t tell them. Everybody does that.”  
Id. at 3. 
148. “Steve Simon, a research biostatistician at Children’s Mercy Hospital in Kansas City, 
Missouri, says that when people participate in more than one clinical trial at a time, it can be 
harmful to people and research. ‘When neither researcher knows about potential interactions 
with the other trial, that raises concerns about scientific validity. . . . You don’t know how 
these things might interact. It’s asking for trouble.’”  
Id. 
149. “Pfizer signed a $75 million agreement Thursday with Nigerian authorities to settle 
criminal and civil charges that the pharmaceutical company illegally tested an experimental 
drug on children during a 1996 meningitis epidemic. . . . Charges filed against Pfizer by 
Nigeria’s federal government, which is seeking about $6 billion in damages, are unaffected 
by the settlement.”  
Joe Stephens, Pfizer to Pay $75 Million to Settle Trovan-Testing Suit, WASH. POST, July 31, 
2009, at A15. 
150. Joe Stephens, Pfizer Reaches Settlement in Nigerian Drug-Trial Case, WASH. 
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both IRB oversight of proposed clinical trials and government oversight of 
private IRBs. Based on a previously rejected (and dangerous151) application, the 
Government Accountability Office proposed a fake clinical trial and submitted 
it to three private IRBs, in which one (Coast IRB152) approved the study. The 
GAO also created a transparently fictitious IRB153 to see if the Department of 
Health and Human Services would register it. It did. Large surveys also 
continue to show that there are pervasive conflicts of interest between IRBs and 
industry.154 This all suggests that the very system deferred to by the IOM as 
being presumptively virtuous enough to soften the current “strong 
protectionist” stance on prison research is questionable at best. Moreover, it 
highlights the extent to which the conditions that shape human subjects abuse 
are not simply those that come from the living conditions of participants, but 
also those that shape the financial interests of the industries conducting the 
research. While there has been conversation about the changes needed in prison 
environments before such research can be truly ethical, there needs to be more 
thought about the changes that need to occur within the research industry 
before they are once again given greater access to prison populations.  
3. Substantive Critique 
This leads to the third critique: isolating the ethical questions surrounding 
the use of prisoners as human subjects from broader normative paradigms 
directly relevant to prisoners’ daily lives–most importantly, human rights–may 
obscure the full impact of the IOM recommendations. The methodological 
critique concerned itself with how the IOM Committee came to its 
                                                                                                             
POST, Apr. 4, 2009, at A3. 
151. A reviewer from one of the IRBs that rejected the fake GAO clinical trial proposal 
said, “We realized it was a terrible risk for the patient . . It is the worst thing I have ever 
seen.” Alicia Mundy, Sting Operation Exposes Gaps in Oversight of Human Experiments, 
WALL ST. J., Mar. 26, 2009, available at http://online.wsj.com/article/SB12381117957235 
3181.html.  
152. Jesse Reynolds notes, 
Coast seems to epitomize the shortcomings of private companies which approve research on 
humans. It advertises its fast 48 hour turnaround time on submissions, and even publishes a 
coupon for a free review, offering prospective customers to “take us for a free test drive” and 
to “coast through your next study.” In the last five years, Coast approved all 356 submitted 
protocols. And in the case of the GAO’s faked application, Coast didn’t even examine the 
submitted data. 
Jesse Reynolds, Human Research Subjects Protection: Under Fire From Congress, 
BIOPOLITICAL TIMES, Mar. 31, 2009, http://www.biopoliticaltimes.org/article.php?id=4614.  
153. “The committee, working with the Government Accountability Office, Congress’s 
investigatory arm, named the CEO of the fake IRB Truper Dawg, after a staffer’s three-
legged dog, now deceased. Other fake names included ‘April Phuls’ and “Timothy Wittless,” 
which lawmakers said should have signaled irregularities to HHS. The department registered 
the IRB.” Mundy, supra note 151. 
154. See, e.g., Eric G. Campbell et al., Financial Relationships Between Institutional 
Review Board Members and Industry, 355 NEW ENG. J. MED. 2321 (2006).  
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recommendations and the contextual critique examined which set of conditions 
the Committee acknowledged as relevant to its deliberations. This substantive 
critique deals with how the Committee engages the substance of its ethical 
deliberations with other normative paradigms relevant to the treatment of 
human subjects. Notably, the IOM’s failure to meaningfully engage with 
established human rights norms and standards—such as those laid out in the 
Universal Declaration of Human Rights—is troubling. To be sure, the IOM 
discusses the ways in which prison settings complicate traditional notions of 
informed consent and non-coercion. But it is one thing to discuss these 
complications as merely a matter of research ethics. It is quite another to 
engage them as a matter of human rights.  
Although the Institute of Medicine might resist this type of dual 
engagement with both ethics and human rights as being too far afield from its 
mandate and area of expertise, such responses to this critique fail to 
acknowledge the interconnected nature of biomedical ethics and human 
rights.155 University of Pennsylvania bioethicist Arthur Caplan has noted, 
“bioethics was born from the ashes of the Holocaust.”156 Similarly, human 
rights took on a new importance during this period. George Annas notes in his 
timely book American Bioethics: Crossing Human Rights and Health Law 
Boundaries that ethics and human rights “have a natural symbiosis . . . [that] 
can be most closely discerned in crimes against humanity that have historically 
involved physicians, such as torture, imprisonment, execution, and lethal 
human experimentation.”157 This passage draws attention to the unique role 
prisoners have played in the development of ethics and international human 
rights. While they are often considered to be two distinct fields, a growing 
number of scholars are realizing that “[h]uman rights and medical ethics are 
complementary, and the use of the two together maximizes the protection 
available to the vulnerable patient.”158  
Michael Peel identifies at least two differences between human rights and 
ethics.  First, human rights “focus[es] on state-level action rather than a person-
to-person relationship.”159 Second, the notion of benevolence—at the heart of 
any ethical discussion—is absent from human rights in that “rights do not 
depend on the empathy of other actors.”160 Despite these distinctions, bringing 
                                                
155. An example of the increasing awareness of the relationship between bioethics and 
human rights can be seen in UNESCO’s UNIVERSAL DECLARATION OF BIOETHICS AND 
HUMAN RIGHTS (2005).  See generally Roberto Andorno, Global Bioethics at UNESCO: In 
Defence of the Universal Declaration on Bioethics and Human Rights, 33 J. MED. ETHICS 
150 (2007).    
156. GEORGE J. ANNAS, AMERICAN BIOETHICS: CROSSING HUMAN RIGHTS AND HEALTH 
LAW BOUNDARIES 161 (2005).  
157. Id. at xiv. 
158. Michael Peel, Human Rights and Medical Ethics 98 J. ROYAL SOC’Y. MED. 171, 
173 (2005).  
159. Id. at 172.  
160. Id. 
41_82_OBASOGIE-PRINTER PROOF.DOC 11/9/10  4:30 PM 
Apr. 2010] PRISONERS AS HUMAN SUBJECTS 79 
a human rights framework into conversations on the research ethics pertaining 
to prisoners’ participation as human subjects has at least three major benefits. 
First, human rights “give fundamental protections that allow equal participation 
in a democracy….[that] prevent the worst excesses of democracy because no 
society can vote to take those rights away.”161 For prisoners who have most of 
their freedoms restricted, a human rights framing draws attention to core rights 
that may not receive the same sensitivity under a unilateral focus on research 
ethics. Second, “conventional bioethics has difficulty addressing broad issues 
of inequity,”162 an issue that is at the center of any human rights analysis. 
Lastly, bioethics’ emphasis on individual autonomy163 can mask how group 
dynamics can lead individuals to choose to partake in research that may 
ultimately lead to unethical if not harmful outcomes. Human rights frameworks 
offer a safety net to ensure that bioethics’ privileging of individual autonomy 
over other principles does not trump core rights that vest in every human. 
The connections between bioethics and human rights is far from 
coincidental; vesting internationally agreed upon rights in every person and 
creating ethical standards for research involving human subjects were and 
continue to be seen as two sides of the same coin shielding humanity from 
reliving its darkest moments. As Annas points out in American Bioethics, this is 
evident in the documents discussing these normative commitments: 
The voluntary consent of the human subject is absolutely essential. This 
means that the person involved should have legal capacity to give consent; 
should be so situated as to be able to exercise free power of choice, without 
the intervention of any element of force, fraud, deceit, duress, over-reaching, 
or other ulterior form of constraint or coercion . . . .164  
 
Everyone has the right to a standard of living adequate for the heath and well-
being of himself and of his family, including food, clothing, housing and 
medical care and necessary social services . . . .165  
As a whole and in their cited portions, these documents take on two separate 
issues—one placing informed consent and non-coercion at the cornerstone of 
all ethical human subject research, the other addressing the human right to 
medical care. Together, however, they make a more perfect union: that 
biomedical ethics—and in particular, research ethics—are most legitimate 
when subjects’ human rights are secure. It makes little sense for ethical 
                                                
161. Id. at 171.  
162. Paul Farmer and Nicole Gastuneau Campos, New Malaise: Bioethics and Human 
Rights in the Global Era, 32 J.L. MED. & ETHICS 243, 245 (2004). 
163. See generally Paul Root Wolpe, The Triumph of Autonomy in American Bioethics: 
A Sociological View, in Bioethics and Society: Constructing the Ethical Landscape 
(Raymond DeVries & Janardan Subedi, eds., 1998). 
164. The Nuremberg Code (1947), available at http://www.hhs.gov/ohrp/references/ 
nurcode.htm. 
165. Universal Declaration of Human Rights, G.A. Res. 217 (III) A, U.N. Doc. 
A/RES/217(III) (Dec. 10, 1948). 
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inquiries to isolate themselves from human rights. Continuing to do so can lead 
to situations where ethics can be misused to exacerbate human rights 
violations; subjects living in conditions where basic human rights are not 
upheld might agree to participate in studies that they otherwise might not—a 
subtle but important form of coercion. 
The wide-ranging human rights violations documented in prisons by 
organizations such as the ACLU and Human Rights Watch suggest that 
conditions are often deplorable: inadequate medical care, unprovoked physical 
assaults, and sexual coercion are but a few of these concerns.166 And the 
relations between guards and prison populations raise even brighter human 
rights red flags. As an example, an October 2006 Human Rights Watch report 
documents how many prisons routinely use terror tactics such as subjecting 
prisoners to snarling guard dogs as population control measures.167  
Biomedical and research ethics are not the only source of normative 
commitments by which physicians and researchers should abide. As such, the 
ethical challenges raised by proposals to loosen current restrictions on using 
prisoners as human subjects may very well be a tremendous opportunity to 
fully integrate ethical deliberations with human rights sensibilities. What makes 
their integration so urgent is that without it, one set of norms developed to 
protect vulnerable subjects can be used unwittingly to destabilize the other. To 
prevent this, ethical and human rights frameworks must be seen as 
interconnected rather than disjoined. Otherwise, one ethic for treating people 
with dignity can be paradoxically used to exploit holes in the other—a 
strikingly unfortunate ethical outcome for subjects caught in the crosshairs. 
Is it possible to conduct ethical research with prisoners in a way that is 
consistent with various human rights norms? This is an important empirical and 
legal question that is beyond this Part’s narrow focus on a substantive deficit 
within the IOM’s chosen ethical framework.168 But without this deeper analysis 
and integrated framework that substantively brings both ethical and human 
rights considerations directly into its policy deliberations, the IOM’s 
                                                
166. For example, California’s prison health care system was deemed to be so 
substandard and harmful to prisoners, a federal district court judge placed it under 
receivership. The court noted, “By all accounts, the California prison medical care system is 
broken beyond repair. The harm already done in this case to California’s prison inmate 
population could not be more grave, and the threat of future injury and death is virtually 
guaranteed in the absence of drastic action.” Findings of Fact and Conclusions of Law Re 
Appointment of Receiver at 1, Plata v. Schwarzenegger, No. C01-1351 TEH (N.D. Cal. Oct. 
3, 2005), available at http://www.cprinc.org/docs/court/PlataFindingsFactConclusionsLaw 
1005.pdf. See generally HUMAN RIGHTS WATCH, NO ESCAPE: MALE RAPE IN PRISON (2001), 
available at http://www.hrw.org/reports/2001/prison/index.htm; HUMAN RIGHTS WATCH, 
ALL TOO FAMILIAR: SEXUAL ABUSE OF WOMEN IN U.S. STATE PRISONS (1996), available at 
http://www.hrw.org/reports/1996/Us1.htm. 
167. See generally HUMAN RIGHTS WATCH, CRUEL AND DEGRADING: THE USE OF DOGS 
FOR CELL EXTRACTIONS IN U.S. PRISONS (2006).  
168. For an interesting discussion on the problems associated with research in today’s 
prisons, see Reiter, supra note 1, at 520-34. 
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recommendation to loosen current restrictions might have the unintended 
effects of exposing prisoners to additional health risks and exacerbating 
ongoing human rights violations.  
CONCLUSION 
To date, the recommendations put forth by the 2006 IOM report have not 
led to any changes in the regulations governing human subjects research with 
prisoners, although changes to Subpart C are still under consideration. This 
Article argued that the recommendations put forth by the IOM should not be 
adopted due to (1) its methodological shortcomings that forgo an empirical 
understanding of how research ethics interact with prison conditions in favor of 
a literature review, (2) its contextual limitations that situate prisoners’ 
vulnerability to abuse as only a product of prison conditions rather than also 
looking at how market conditions might exacerbate such concerns, and (3) its 
substantive limitations whereby the proposed ethical  framework fails to engage 
other normative commitments relevant to human subject protection such as 
human rights. Before the Department of Health and Human Services moves 
forward with any further consideration of the IOM report, these issues should 
be taken seriously. 
It is likely that state and federal governments will continue to face 
numerous ethical dilemmas involving prisoners. As an example, lawmakers in 
South Carolina have considered legislation that attempts to relieve the state’s 
kidney shortage by shaving 180 days off inmates’ sentences if they agree to 
become organ donors.169 Further developments in human biotechnology may 
also come into play. A tremendous amount of excitement has centered around 
the therapeutic potential of human embryonic stem cell research. And, given 
the shortage of eggs available to pursue certain types of stem cell research with 
human embryos,170 it is not difficult to imagine a state providing similar 
incentives to incarcerated women who might agree to become egg donors. 
Outside of the prison environment, ethics are also likely to impact regulatory 
policy and administrative agencies over the next several years, whether it is the 
appropriate regulation of reproductive and genetic technologies by the Food 
and Drug Administration or other regulatory bodies, increased oversight of 
direct-to-consumer genetic tests by the Federal Trade Commission, or increased 
oversight of the use of genetic technologies by the Justice Department.  
These are complicated issues, pitting what some might call the ability to 
save and improve human life against maintaining all people’s human dignity. 
What is important is that as biomedical and research ethics are sought to inform 
                                                
169. See generally Associated Press, Wanna Cut Your Jail Time? Donate A Kidney!, 
CBSNEWS.COM, Mar. 8, 2007, http://www.cbsnews.com/stories/2007/03/08/national/main 
2548860.shtml. 
170. See generally Geoff Brumfiel, Egg Shortage Hits Race to Clone Human Stem 
Cells, 453 NATURE 828 (June 11, 2008). 
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increasing areas of regulatory policy that there is a broad recognition that 
ethics are not, in and of themselves, a source of public policy. While the 
contribution of ethical inquiries are invaluable, this Article has argued that too 
much is at stake when such policy recommendations are not methodologically 
robust, do not acknowledge the rich and overlapping contexts that inform the 
issue, and isolate one set of moral principles without a substantive engagement 
with other relevant norms. Regrettably, in these and other failures, the IOM’s 
report may very well come to stand for the proposition of how not to infuse 
ethics into regulatory policy. 
 
 
